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Abstract
HIV-associated neurocognitive disorders (HAND) affect 30% of infected patients despite suppressive
antiretroviral therapy (ART) and are associated with chronic immune activation and oxidative stress within
the systemic circulation and central nervous system (CNS). Pathological studies of post-mortem brain
parenchyma indicate productive HIV replication in brain macrophages/microglia and restricted infection in
some astrocytes, while analyses of cerebrospinal fluid (CSF) suggest infiltrating T lymphocytes as another
CNS HIV cellular reservoir. In vitro studies have linked macrophage HIV infection and immune activation of
macrophages and astrocytes with release of glutamate, reactive oxygen species, and pro-inflammatory
cytokines, each of which is implicated in HAND neuropathogenesis. The increased immune activation and
oxidative stress detected in blood and CSF of ART-treated individuals suggests that these processes could be
targeted for neuroprotection. Accordingly, we previously identified a correlation between HAND and reduced
protein expression of brain heme oxygenase-1 (HO-1), a highly inducible detoxifying enzyme with
antioxidant and anti-inflammatory functions. We further demonstrated that HIV infection of macrophages
reduces HO-1 RNA and protein and that this HO-1 loss is associated with neurotoxic levels of extracellular
glutamate.
We now demonstrate a second potential mechanism driving reduced expression of HO-1 protein in the brain
that can be linked to immune activation and oxidative stress during HIV infection: proteasome-mediated
HO-1 degradation in astrocytes chronically exposed to IFNγ, an HIV-associated CNS immune activator. We
show that HO-1 protein loss in HIV-infected brain correlates with induction of IFNγ-inducible
immunoproteasome subunits and is accompanied by increased HO-1 RNA; we also identified increased
astrocyte immunoproteasome expression in these brains. In our in vitro models, prolonged exposure of
human astrocytes, but not rodent astrocytes, to IFNγ post-transcriptionally reduced expression of HO-1
protein in a time and dose-dependent manner in association with induction of immunoproteasomes and loss
of constitutive proteasomes. Furthermore, IFNγ reduced HO-1 protein half-life by two-fold, and this was
blocked by proteasome inhibition. Our work thus suggests causal links between CNS immune activation,
immunoproteasome induction, and enhanced HO-1 degradation that could contribute to neuropathogenesis
not only in HAND but also other neurodegenerative disorders associated with increased IFNγ, chronic
immune activation and oxidative stress.
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ABSTRACT 
 
IFNγ SELECTIVELY INDUCES ASTROCYTE HEME OXYGENASE-1 DEGRADATION:             
A NOVEL PROTEASOME ROLE IN HIV NEUROPATHOGENESIS 
Colleen E. Kovacsics 
Dennis L. Kolson 
 
HIV-associated neurocognitive disorders (HAND) affect 30% of infected patients despite 
suppressive antiretroviral therapy (ART) and are associated with chronic immune activation and 
oxidative stress within the systemic circulation and central nervous system (CNS). Pathological 
studies of post-mortem brain parenchyma indicate productive HIV replication in brain 
macrophages/microglia and restricted infection in some astrocytes, while analyses of 
cerebrospinal fluid (CSF) suggest infiltrating T lymphocytes as another CNS HIV cellular 
reservoir. In vitro studies have linked macrophage HIV infection and immune activation of 
macrophages and astrocytes with release of glutamate, reactive oxygen species, and pro-
inflammatory cytokines, each of which is implicated in HAND neuropathogenesis. The increased 
immune activation and oxidative stress detected in blood and CSF of ART-treated individuals 
suggests that these processes could be targeted for neuroprotection. Accordingly, we previously 
identified a correlation between HAND and reduced protein expression of brain heme oxygenase-
1 (HO-1), a highly inducible detoxifying enzyme with antioxidant and anti-inflammatory functions. 
We further demonstrated that HIV infection of macrophages reduces HO-1 RNA and protein and 
that this HO-1 loss is associated with neurotoxic levels of extracellular glutamate. 
We now demonstrate a second potential mechanism driving reduced expression of HO-1 protein 
in the brain that can be linked to immune activation and oxidative stress during HIV infection: 
proteasome-mediated HO-1 degradation in astrocytes chronically exposed to IFNγ, an HIV-
associated CNS immune activator. We show that HO-1 protein loss in HIV-infected brain 
correlates with induction of IFNγ-inducible immunoproteasome subunits and is accompanied by 
increased HO-1 RNA; we also identified increased astrocyte immunoproteasome expression in 
these brains. In our in vitro models, prolonged exposure of human astrocytes, but not rodent 
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astrocytes, to IFNγ post-transcriptionally reduced expression of HO-1 protein in a time and dose-
dependent manner in association with induction of immunoproteasomes and loss of constitutive 
proteasomes. Furthermore, IFNγ reduced HO-1 protein half-life by two-fold, and this was blocked 
by proteasome inhibition. Our work thus suggests causal links between CNS immune activation, 
immunoproteasome induction, and enhanced HO-1 degradation that could contribute to 
neuropathogenesis not only in HAND but also other neurodegenerative disorders associated with 
increased IFNγ, chronic immune activation and oxidative stress. 
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CHAPTER 1: INTRODUCTION 
2  
1.1  Pathogenesis of HIV Infection and HIV-Associated Neurocognitive Disorders 
(HAND)  
The human immunodeficiency virus (HIV) is an enveloped virus with a single-stranded RNA 
genome, 2 copies of which are present in the virion. HIV is a member of the Retroviridae family 
and genus Lentivirus and is the causative agent of acquired immunodeficiency syndrome (AIDS). 
Before the advent of life-saving antiretroviral therapy (ART), HIV infection was considered a 
rapidly lethal disease, with an average survival time after infection of 9-11 years (1). ART has 
fundamentally changed the course of this disease into a manageable, chronic condition and today 
a 20-year old individual with HIV infection starting on ART has a normal life expectancy (2). 
Despite the many benefits of ART, HIV infection remains a global public health concern. 
According to the most recently available data, an estimated 36.9 million people worldwide were 
infected with human immunodeficiency virus (HIV) in 2014 and approximately 2 million people 
became newly infected with HIV (3).  
 
HIV shares the genetic structure common to retroviruses and the viral genome contains three 
major structural genes: gag, pol, and env, which encode polyproteins important for virion 
formation and release, reverse transcription, viral DNA integration, and viral precursor protein 
processing, and entry of viral particles into target cells, respectively (4-11). In addition, the HIV 
genome codes for regulatory proteins (Rev, Tat) that promote viral transcription and accessory 
proteins (Nef, Vif, Vpr, Vpu) that although not essential to viral replication, promote viral 
replication within target cells but counteracting anti-viral host defense mechanisms (12-19). 
Translation of the env gene produces the gp160 precursor protein that is further processed by 
endogenous proteases to the viral envelope proteins gp120 and gp41 (10). HIV entry into cells is 
dependent on interactions of gp120 and gp41 with CD4 protein expressed on the surface of host 
cells (11). HIV tropism is thus limited to CD4-expressing cells of the immune system including 
CD4+ T cells, monocytes, macrophages, microglia, and dendritic cells. Although required, CD4 
expression is not sufficient for HIV entry and expression of either CCR5 or CXCR4 coreceptors is 
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necessary for HIV-1 infection (20-23). Additionally, limited, non-productive infection of astrocytes 
has been reported and is mediated by a CD4-independent mechanism of entry. 
 
HIV infection occurs exclusively in humans and transmission occurs when bodily fluids from an 
HIV-infected individual come into contact with mucous membrane, damaged tissue, or the 
bloodstream and the most common modes of HIV transmission are sexual intercourse and 
sharing of equipment used for intravascular drug use (24). During the acute phase of infection (2-
4 weeks), HIV rapidly replicates within CD4+ T cells and leads to high levels of virus in the blood 
(viremia), seeding of gut-associated lymphoid tissue, and a rapid decline in CD4+ cells due to 
HIV induced cell lysis (25-27). The initial stage of infection subsides when the host mounts a 
virus-specific immune response characterized by appearance of antibodies against HIV 
(seroconversion) and activation of a CD8+ T cell response which results in reduced levels of 
circulating virus and partial rebound of CD4+ T cells (27). This host immune response is 
incompletely effective in controlling HIV, leading to the establishment of chronic infection and a 
state of generalized immune activation. Without ART treatment, over a period of years the period 
of clinical latency ends as viremia rebounds, CD4+ T cell counts drop, and there is a progressive 
failure of the immune system ultimately leading to development of Acquired Immunodeficiency 
Syndrome (AIDS). ART treatment significantly reduces viral replication and associated morbidity 
and mortality, especially when initiated early after initial infection. (28, 29) 
 
Although the introduction and widespread use of ART has changed the clinical course of HIV 
infection, neurological complications of HIV infection persist at significant rates in HIV-infected 
individuals and remain a significant clinical challenge, as underscored by the 3-fold higher risk of 
mortality in infected individuals diagnosed with HIV-associated neurocognitive disorders (HAND) 
(30, 31). HAND are a collection of cognitive, motor, and behavioral deficits of varying severity and 
although the prevalence of the most severe form of HAND, HIV-associated dementia (HAD), has 
decreased since the introduction of ART, the prevalence of milder forms of HAND, asymptomatic 
neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), has remained 
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unchanged or even increased (31-33). Early after initial infection, HIV-infected monocytes and/or 
lymphocytes from the periphery traffic into the central nervous system (CNS) and establish 
productive infection in resident monocyte-derived macrophage (MDM) and microglia cells (34-37). 
Although neurons are not infected by HIV, neuronal death, loss of synaptic complexity and 
plasticity, and altered neuronal metabolism occurs in HIV-infected individuals, including those on 
suppressive ART (38-40). Persistent infection within MDM/microglia drives release of factors that 
are directly neurotoxic and also indirectly neurotoxic by promoting activation of uninfected MDM, 
microglia, and astrocytes and recruitment of additional macrophages and T cells to the CNS, thus 
amplifying HIV-associated inflammation and neurotoxicity (41-49).  
 
Systemic and CNS markers of monocyte/macrophage activation predict neurocognitive 
impairment and severity of HAND correlates with monocyte infiltration and MDM/microglial 
activation, highlighting a critical role of HIV-infected MDM/microglia in the neuropathology of 
HAND (50-56). A substantial proportion of HIV-infected individuals on suppressive ART show 
evidence of persistent CNS MDM/microglia activation and low grade intrathecal inflammation (42, 
57, 58). Chronic immune activation is associated with increased levels of TNFα and IFNγ in 
plasma, CSF, and brain parenchyma of HIV-infected individuals, including those on ART, and are 
associated with neurocognitive impairment and HAND (54, 58-67). Peripheral immune activation 
also contributes to neurocognitive impairment in HIV-infected individuals, and is associated not 
only with ongoing HIV replication, but also with microbial translocation, loss of immunoregulatory 
cells, elevated type I and II IFN, and altered cytokine/chemokine production (68-71). HIV-driven 
damage to gut-associated lymphoid tissue enhances the translocation of microbial products, such 
as lipopolysaccharide (LPS), into the systemic circulation and increased LPS in the plasma of 
HIV-infected individuals is associated with monocyte activation and severity of HAND (72-74). 
 
HIV infection is associated with reduced levels of glutathione in plasma, lymphocytes, PBMCs, 
and monocytes, reduced thioredoxin in HIV-infected cells, and elevated lipid peroxidation 
products, indicating oxidative stress in systemic compartments (75-80). Chronic immune 
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activation during HIV infection can also induce CNS oxidative stress, which enhances HIV 
replication, inflammatory cytokine release, and neurotoxin production, further promoting neuronal 
dysfunction in HIV-infected individuals (81-87). Markers of oxidative stress including ceramide, 
sphingomyelin, and 4-hydroxynonenals (4-HNE) are associated with and predictive of worsening 
neurocognitive impairment (86, 88). In sum, these data establish a crucial role for 
macrophages/microglia, chronic immune activation, and oxidative stress in mediating neuronal 
dysfunction and HAND. 
 
1.2 Heme Oxygenase-1 and the Endogenous Antioxidant Response  
Disturbances in cellular redox balance resulting from overproduction of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS), and/or diminished antioxidant capacity may result in 
the oxidation of cellular macromolecules, including proteins, lipids, and nucleic acids (89-91). 
Oxidative stress has been implicated in the pathogenesis of numerous neurodegenerative 
diseases, including HAND, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, and Multiple Sclerosis (MS) (89, 92-96).  
 
Cellular defense against oxidative stress is mediated by free radical scavenging molecules such 
as glutathione and expression of antioxidant enzymes that detoxify ROS. The endogenous 
antioxidant response is coordinately induced by nuclear factor erythroid 2-related factor 2 (Nrf2) 
that activates the transcription of a large coalition of genes sharing a common promoter element 
termed the antioxidant response element (ARE) (97). Under conditions of oxidative stress, Nrf2 
translocates to the nucleus to drive expression of detoxifying genes including heme oxygenase-1 
(HO-1), glutathione peroxidase-1 (GPX1), and NAD(P)H quinone oxidoreductase 1 (NQO1). ARE 
driven gene products have numerous cytoprotective functions including metabolism, phase II 
detoxification, glutathione biosynthesis, peroxidation, heat shock protein responses, and 
modulation of immune and inflammatory stimuli (98).  
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HO-1 is the inducible isoform of the heme oxygenase (HO) enzyme, which catalyzes the 
degradation of heme and ultimately leads to the generation of equimolar amounts of carbon 
monoxide, bilirubin, and iron. HO-1 is a critical effector for limiting acute cellular injury and is 
rapidly induced in response to numerous cellular insults including excess heme, reactive oxygen 
species, inflammation, heavy metals, and hypoxia. The protective effects of HO-1 have been 
linked to its enzymatic degradation of the pro-oxidant heme and subsequent generation of carbon 
monoxide and bilirubin, which have anti-inflammatory and antioxidant properties; in addition 
nonenzymatic cytoprotective functions have also been proposed (99-101). A genetically distinct 
isoform, heme oxygenase-2 (HO-2), is constitutively expressed and not under control of Nrf2, and 
considered important for regulating heme under homeostatic conditions. Within the brain, HO-2 is 
ubiquitously expressed but HO-1 is often undetectable in neurons of individuals without CNS 
disease and appears to be primarily expressed in astrocytes, macrophages, and microglia in the 
normal/non-injured brain (102, 103).  
 
We previously identified a deficiency of HO-1 protein in the brains of individuals with HAND, 
which represents the first neurodegenerative disorder to be associated with a deficiency of brain 
heme oxygenase expression and further showed that HO-1 deficiency is linked to glutamate 
dysregulation in cultured HIV-infected macrophages (104). In our in vitro model of HIV-induced 
neurodegeneration, HIV infection of macrophages (a major reservoir for HIV replication in the 
brain) results in profound reduction of HO-1 RNA and protein expression and production of 
neurotoxic levels of glutamate; this excessive glutamate production can be suppressed by 
restoring HO-1 expression in the macrophages to pre-infection levels (105, 106). The parallel 
decrease in HO-1 mRNA and protein in HIV-infected macrophages suggests a transcriptional 
mechanism of HO-1 suppression in infected macrophages. These findings implicate HO-1 
deficiency as contributing factor for development of HAND and suggest that induction of HO-1 
may provide neuroprotective benefit in HIV-infected individuals. 
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1.3 The Ubiquitin Proteasome System 
The ubiquitin proteasome system (UPS) is the major pathway of intracellular protein degradation 
and activity of proteasome complexes is critical for maintaining proteostasis across a variety of 
physiological and pathological states. The ubiquitin (Ub) component of the UPS selectively 
targets proteins for degradation through a multistep process of attachment of Ub to substrate 
proteins and degradation of ubiquitinated proteins is mediated by proteolytic activity of the 
proteasome complex (107). Catalytic activity is conferred by 20s core subunit composed of two 
outer rings containing 7 distinct α subunits and 2 rings containing 7 distinct β subunits and 
arranged as α1-7 β1-7 β1-7 α1-7. The β1, β2, and β5 subunits possesses catalytic activity and have 
distinct preferences for cleaving after acidic (caspase-like), basic (trypsin-like), and hydrophobic 
(chymotrypsin-like) residues, respectively (108). IFNγ induces expression of distinct catalytic 
subunits, LMP2, MECL-1, and LMP7, that are incorporated into de novo immunoproteasome 
complexes in place of their constitutive counterparts β1, β2, and β5. In immunoproteasomes, 
LMP2 displays both chymotrypsin-like and trypsin-like activity and is substituted for β1, MECL-1 
is substituted for β2 but both subunits display similar trypsin-like activity, and LMP7 displays both 
chymotrypsin-like and trypsin-like activity and is substituted for β5 (109-111).  
 
Complete 26s constitutive proteasome complexes (Fig. 1.1A) are typically capped on both ends 
by the 19S regulatory subunit, consisting of 6 ATPase subunits and 2 non-ATPase subunits, 
while complete 26s immunoproteasome complexes (Fig. 1.1B) are typically capped on both ends 
by the IFNγ-inducible 11s regulatory subunit, consisting of the IFNγ-inducible PA28α and PA28β 
subunits arranged as a heptamer (112). The 19s and 11s regulatory subunits physically interact 
with the 20s α rings and control the recognition, unfolding, and entry of substrates into the 20s 
catalytic core. Expression of distinct catalytic and regulatory subunits alters the kinetics, cleavage 
site preference, and cleavage site usage in immunoproteasome complexes as compared to 
constitutive proteasome complexes (113-115). The distinct properties of immunoproteasomes 
also confer different functions to these complexes that are involved in generation of antigenic 
peptides for MHC class I presentation, regulation of the expression of inflammatory mediators, 
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partial degradation of proteins to active forms, and degradation of oxidized proteins (114, 116-
118). 
 
 
Figure 1.1 Composition of constitutive and immunoproteasome complexes. 
Schematic representation of subunits incorporated into proteasome complexes. The 20s catalytic 
core complex contains 2 outer rings of 7 α subunits and 2 inner rings of 7 β subunits. (A) Catalytic 
activity of constitutive proteasome complexes is conferred by the β1, β2, and β5 subunits 
incorporated into the 20s core. Complete constitutive proteasome complexes are generally 
capped on both ends by the 19s regulatory subunit, consisting of 6 ATPase and 2 non-ATPase 
subunits. (B) Catalytic activity of immunoproteasome complexes is conferred by the IFNγ-
inducible LMP2, MECL1, and LMP7 subunits incorporated into the 20s core. Complete 
immunoproteasome complexes are generally capped on both ends by the 11s regulatory subunit, 
consisting of the IFNγ-inducible PA28α and PA28β subunits.  
 
Despite the differences in constitutive and immunoproteasome complexes described above, both 
subtypes generate qualitatively similar pools of antigenic peptides (119). However, there are 
quantitative differences in the pool of antigenic peptides produced, and immunoproteasomes 
produce peptides with hydrophobic and basic C-terminals at a higher frequency compared to 
constitutive proteasomes (109, 119-123). MHC Class I molecules have higher affinity for 
antigenic peptides with hydrophobic and basic C-terminals, highlighting the importance of 
immunoproteasome activity in MHC Class I antigen presentation and viral clearance (114). The 
quantitative difference in peptide production is thought to reflect the different properties of the 
immunoproteasome catalytic subunits, which confer enhanced chymotrypsin-like and trypsin-like 
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activity and reduces caspase-like activity to immunoproteasome complexes as compared to 
constitutive proteasome complexes (111, 123-125). Additionally, the resolved X-ray structure of 
murine constitutive and immunoproteasome complexes suggests that the structure of the 
constitutive β5 subunit predominantly accommodates cleavage of small hydrophobic residues 
while the immunoproteasome LMP7 subunit structure accommodates cleavage of large non-polar 
residues (126).  
 
Both constitutive and immunoproteasome complexes are formed upon de novo assembly in a 
multistep, regulated process (114, 127). Proteasome assembly is initiated by formation of the 
outer 20s α ring (α1-7) and is followed by the sequential incorporation of the non-catalytic and 
catalytic β subunits into complete precursor complexes (α 1-7 β 1-7 ). The β subunits are initially 
synthesized and incorporated as inactive pro-proteins and autocatalytic processing of the β 
subunits occurs and dimerization of 2 complete precursor complexes produces a fully mature and 
catalytically active 20s complex (114, 128). Formation of 20s proteasome complexes is facilitated 
by several additional factors, including proteasome maturation protein (POMP) (129, 130). POMP 
directly interacts with both constitutive and immunoproteasome precursor complexes and plays 
an important role in the biogenesis of complete proteasome complexes. IFNγ increases 
expression of POMP RNA and the presence of the IFNγ-induced LMP7 subunit enhances the 
kinetics of immunoproteasome assembly and as a result immunoproteasomes are assembled 3-4 
times faster than constitutive proteasomes (131, 132). Additionally, the immunoproteasome 
subunits LMP2 and MECL-1 are incorporated into precursor complexes relatively early and 
facilitate incorporation of LMP7, leading to preferential formation of immunoproteasome 20s 
complexes and exclusion of the constitutive β1, β2, and β5 subunits which are rapidly degraded 
in this “free” form (124, 128, 131, 133, 134). IFNγ does not suppress expression of constitutive 
proteasomes subunits, however the continued preferential formation of immunoproteasomes 
driven by IFNγ leads to a progressive loss of constitutive proteasomes as the pool of pre-existing 
constitutive proteasome complexes is gradually depleted over time with a half-life of 
approximately 5 days that is unaffected by IFNγ (125, 128, 135-139). Analysis of in vivo 
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proteasome content in the liver of mice infected with lymphocytic choriomeningitis virus (LCMV) 
demonstrated that induction of immunoproteasomes and loss of constitutive proteasomes 
occured early, within 2 days after infection, and progressed over time with robust expression of 
immunoproteasomes and near complete loss of constitutive proteasomes by day 8, coinciding 
with a drop in viral titers. On day 12, when virus titers were reduced 100-fold, the ratio of 
immunoproteasome to constitutive proteasome subunits began to decline but still remained 
elevated compared to non-infected livers up to day 25, when no virus is detectable (140). A 
similar induction of immunoproteasomes and dramatic loss of constitutive proteasomes also 
occurred in mice infected with Listeria monocytogenes, indicating that this shift to 
immunoproteasomes is not a response exclusive to viral infection but also be extends to bacteria 
and possibly other pathogens (140). In these in vivo models, the prolonged shift to 
immunoproteasomes did not lead to cell death or otherwise impair general cell functions, 
indicating that immunoproteasomes can perform the numerous homeostatic functions attributed 
to constitutive proteasomes in addition to their specialized functions.  
 
Immunoproteasome induction has been reported in several neurodegenerative diseases including 
HIV-associated neurocognitive disorders (HAND), Alzheimer’s disease, Huntington’s disease, 
ALS, and MS (141-144). Increased expression of immunoproteasome subunits LMP7 and PA28α 
in the dorsolateral prefrontal cortex (DLPFC) and white matter of HIV-infected individuals 
associated with neurocognitive impairment, suggesting a potential role for immunoproteasomes in 
HIV neuropathogenesis (144).   
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2.1 Abstract 
HIV-associated neurocognitive disorders (HAND) affect 30% of infected patients despite 
suppressive antiretroviral therapy (ART), and such disorders associate with chronic immune 
activation and oxidative stress within the systemic circulation and central nervous system (CNS). 
Pathological autopsy studies indicate productive replication of HIV in brain 
macrophages/microglia and restricted infection in some astrocytes, while analyses of 
cerebrospinal fluid have identified infiltrating T lymphocytes as another potential HIV reservoir 
within the CNS. In vitro cell culture models have linked macrophage HIV infection with release of 
neurotoxins, including glutamate, and mediators of oxidative stress, including reactive oxygen 
species, lipid oxidation products, platelet activating factor, pro-inflammatory cytokines, and viral 
proteins, each of which is implicated in HAND neuropathogenesis. Each of these factors, except 
viral proteins, can also be released from non-infected, immune-activated macrophages and 
astrocytes, and the expression of markers of immune activation and oxidative stress in blood and 
cerebrospinal fluid of ART-treated individuals suggests that these other processes, in addition to 
HIV replication, could be targeted for neuroprotection. Accordingly, we previously identified a 
correlation between HAND and reduced expression of brain heme oxygenase-1 (HO-1), a 
ubiquitously expressed, highly inducible detoxifying enzyme with anti-oxidative and anti-
inflammatory functions. We further demonstrated that HIV infection of macrophages reduces HO-
1 RNA and protein and that this HO-1 loss is associated with neurotoxic levels of extracellular 
glutamate that could promote HIV neuropathogenesis.  
 
We now demonstrate a second potential mechanism driving reduced expression of HO-1 protein 
in the brain that can be linked to pathological immune activation and oxidative stress during HIV 
infection: proteasome-mediated HO-1 degradation in astrocytes chronically exposed to IFNγ, an 
HIV-associated CNS immune activator. In our model, we found that prolonged exposure (15 
days) of human fetal astrocytes to IFNγ reduces expression of HO-1 protein while increasing 
expression of immunoproteasome subunits and decreasing expression of constitutive 
proteasome subunits. These effects are time-dependent and not associated with HO-1 RNA 
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reduction. Furthermore, IFNγ treatment reduces astrocyte HO-1 protein half-life by two-fold, and 
this is blocked by a proteasome inhibitor. Finally, we show that HO-1 protein loss in HIV-infected 
brain is accompanied by increased HO-1 RNA expression and that the HO-1 protein loss 
correlates with immunoproteasome expression; we also specifically identified increased astrocyte 
immunoproteasome expression in these brains. Our studies thus suggest causal links between 
CNS immune activation, immunoproteasome induction and enhanced HO-1 degradation, and 
glutamate dysregulation that could contribute to neuropathogenesis not only in HAND but also 
other neurodegenerative disorders associated with increased IFNγ expression.  
 
2.2 Introduction 
Recently we identified a significant reduction in the expression of the phase II detoxifying protein 
heme oxygenase-1 (HO-1) in the brains of individuals with HIV-associated neurocognitive 
disorders (HAND) and further showed that reduced HO-1 protein expression is linked to 
glutamate dysregulation in cultured HIV-infected macrophages (104). We have proposed 
targeting of HO-1 as a therapeutic approach for the treatment and/or prevention of HAND, which 
is the first neurodegenerative disorder demonstrated to be associated with a deficiency of brain 
heme oxygenase expression. In our in vitro model of HIV-induced neurodegeneration, HIV 
infection of macrophages (a major reservoir for HIV replication in the brain) results in profound 
reduction of HO-1 RNA and protein expression and production of neurotoxic levels of glutamate; 
this excessive glutamate production can be suppressed by restoring HO-1 expression in the 
macrophages to pre-infection levels (105, 106). The parallel decrease in HO-1 mRNA and 
protein in HIV-infected macrophages suggests a transcriptional mechanism of HO-1 suppression 
in infected macrophages in the brain, which represent a relatively small fraction of the total 
cellular content of the brain parenchyma. To extend our studies to other brain cell lineages, we 
sought to identify potential mechanisms of HO-1 protein loss in astrocytes, which likely account 
for most of the HO-1 expressed in the brain, and which have been implicated as mediators of 
neuropathological inflammatory responses in HAND.  
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Because HAND remains highly prevalent (30-50%) in antiretroviral therapy (ART)-treated HIV-
infected individuals, neuroprotective strategies that target underlying mechanisms of HAND 
dysfunction must be developed (145-148). This continued prevalence of HAND has been 
attributed to chronic immune activation and oxidative stress within systemic and central 
compartments, which can persist in individuals receiving ART (58, 81, 86). In our previous 
analysis of autopsied brain tissue from HIV-infected individuals we demonstrated a significant 
reduction in HO-1 protein expression in the dorsolateral prefrontal cortex (DLPFC) and further 
showed that reduced HO-1 protein correlated with levels of HIV replication in the prefrontal cortex 
and cerebrospinal fluid, with markers of macrophage/monocyte activation, and with the diagnosis 
of HAND (104). Thus, understanding the mechanisms underlying loss of HO-1 protein in HIV-
infected individuals could reveal novel targets for neuroprotective strategies directed towards 
restoring HO-1 expression.  
 
The decreased brain expression of heme oxygenase that we have identified in HIV-infected 
individuals involves only HO-1, one of the two HO isoforms. The heme oxygenase family consists 
of two genetically distinct isoforms, HO-1 and HO-2, each of which catalyzes the enzymatic 
degradation of free heme. The HO-1 isoform is highly inducible in all cell types except neurons, 
while the HO-2 isoform is constitutively expressed at relatively constant levels in all cell types, 
including neurons. The induction of HO-1 serves a critical function in the host’s response to acute 
cellular injury, including that resulting from immune mediators and oxidative stress (99). The 
cytoprotective effects of HO-1 have been linked to its enzymatic degradation of the pro-oxidant 
heme and subsequent generation of carbon monoxide and bilirubin, which have anti-inflammatory 
and antioxidant properties; in addition nonenzymatic cytoprotective functions have also been 
proposed (99-101). 
 
Several known HO-1 regulatory mechanisms could be perturbed in the brains of HIV-infected 
individuals. Cell culture studies have shown that transcriptional expression of HO-1 is rapidly 
induced (hours) and enzymatic activity may be more rapidly modulated (minutes) through HO-1 
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phosphorylation events (149). Transcription of the HO-1 gene is regulated by both repressive 
and activating factors, including the antioxidant response activator, nuclear factor erythroid 2-
related factor 2 (Nrf2) (150). Nrf2 binds to the antioxidant response element (ARE) present within 
the promoter of HO-1 (HMOX1) and induces expression of more than 200 other cytoprotective 
and detoxifying effector genes, including NAD(P)H dehydrogenase [quinone] 1 (NQO1) and 
glutathione peroxidase 1 (GPX1) (97). Our previous studies showed that the deficiency of HO-1 
protein expression in HAND brain is not accompanied by a deficiency of NQO1 or GPX1, which 
suggests that down-regulation of ARE-driven gene expression is not likely to account for the HO-
1 deficiency. Moreover in this present study we demonstrate that the HO-1 protein loss in HIV-
infected brain samples associates with elevated HO-1 RNA expression, suggesting a post-
transcriptional mechanism of HO-1 loss. Two potential post-transcriptional mechanisms that could 
reduce HO-1 protein expression without reducing RNA expression include decreased HO-1 
mRNA translation and enhanced HO-1 protein degradation (151-154). 
 
Given the associations between reduced expression of HO-1 protein in the brain and markers of 
CNS immune activation, we hypothesized that immune activators associated with HIV infection 
may dysregulate HO-1 expression in astrocytes. We therefore determined the effects of TNFα, 
LPS, and IFNγ on heme oxygenase expression in human primary fetal astrocytes under 
conditions of both short- and long-term exposure, to mimic conditions of acute and chronic HIV 
brain infection relevant to HAND pathogenesis. We now demonstrate that prolonged exposure 
(15 days), but not acute exposure (< 6 days) of human astrocytes to IFNγ recapitulates the post-
transcriptional HO-1 protein loss observed in HIV-infected brain tissue and we identify enhanced 
HO-1 protein degradation as a likely mechanism for this effect. The enhanced HO-1 protein loss 
is accompanied by increased expression of immunoproteasome subunits. The ubiquitin 
proteasome system (UPS) is the major pathway of intracellular protein degradation and activity of 
proteasome complexes is critical for maintaining proteostasis across a variety of physiological 
and pathological states. IFNγ reshapes the UPS by inducing expression of distinct catalytic and 
regulatory proteasome subunits that incorporate to form immunoproteasome complexes which 
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have altered kinetics, cleavage site preference and usage, and substrate requirements compared 
to the constitutively expressed proteasome complexes that they replace (113-115). Within the 
CNS of HIV-infected individuals, IFNγ is significantly elevated, even in aviremic patients, and we 
previously showed that immunoproteasomes are induced within the prefrontal cortex of HIV-
infected individuals (54, 61, 62, 144). Here we show that HO-1 protein expression is negatively 
correlated with immunoproteasome expression within the DLPFC of HIV-infected individuals and 
identify astrocytes as a cellular site of immunoproteasome induction in the prefrontal cortex. 
Furthermore, our in vitro studies demonstrate that induction of immunoproteasomes and 
concurrent loss of constitutive proteasomes drives reduced expression of HO-1 protein in 
astrocytes exposed to IFNγ and pulse chase experiments implicate enhanced degradation of HO-
1 protein by immunoproteasomes as a likely underlying mechanism. Thus, we have identified 
IFNγ as a plausible mediator of HIV-associated HO-1 protein loss in the brain and implicated 
enhanced degradation by immunoproteasomes as a novel mechanism for HO-1 regulation.  
 
2.3 Materials and Methods 
Study Approvals 
All National NeuroAIDS Tissue Consortium (NNTC) studies were conducted in accordance with 
human subject protection protocols at participating institutions. Written consent was obtained for 
subjects at four collection sites in the USA. The following offices maintained the IRBs that 
provided oversight for the protection of human subjects: (a) The University of Texas Medical 
Branch Office of Research Subjects Protections, Galveston, Texas, USA; (b) Mount Sinai Medical 
Center Program for the Protection of Human Subjects, New York, New York, USA; (c) University 
of California, San Diego, Human Research Protections Program, San Diego, California, USA; (d) 
University of California, Los Angeles, Office of the Human Research Protection Program, Los 
Angeles, California, USA. Human primary fetal astrocyte cultures obtained from the Temple 
University Comprehensive NeuroAIDS Center (CNAC) were prepared from fetal brain tissue 
obtained from elective abortion procedures performed in full compliance with National Institutes of 
Health and Temple University ethical guidelines and approved by the IRB of Temple University. 
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The National NeuroAIDS Tissue Consortium (NNTC)  
Established in 1998, the NNTC collects, stores, and distributes blood, cerebrospinal fluid (CSF), 
and tissue samples from well-characterized HIV-positive individuals and HIV-negative individuals. 
HIV-positive individuals are recruited for longitudinal observational studies that include 
assessment of neurological, neuropsychological, and neuropsychiatric domains and collection of 
blood, CSF, and urine at clinic visits occurring every 6-24 months. Detailed pathological 
evaluations of brain, spinal cord, and peripheral organs were performed post-mortem and 
samples were banked according to established protocols.  
Processing and banking of brain tissue  
At autopsy the brain was removed, visually inspected for abnormalities, bisected longitudinally, 
and cerebral hemispheres were coronally sliced at 0.8 to 1.0 cm intervals. Sections for 
biochemical analyses were flash frozen either directly in liquid nitrogen or sandwiched between 
pre-chilled aluminum plates, and then stored at -80°C. Sections for immunohistochemical 
analyses were fixed in 10% phosphate buffered formalin for 24 hours, dissected into 1 to 2 cm3 
blocks, and paraffin embedded.  
Subjects in DLPFC cohort 
A cohort of 90 HIV-infected (HIV+) and 66 non-infected (HIV-) cases was selected from the 
NNTC autopsy cohort and brain tissue samples were assembled by the Texas NeuroAIDS 
Research Center (144, 155). NNTC site neuropathologists rendered nosological diagnosis of HIV 
encephalitis (HIVE) as guided by the criteria of Budka et al, and among the 90 HIV+ cases, 14 
subjects had pathologically confirmed encephalitis (HIVE) and 76 subjects did not have HIVE 
(HIV+/HIVE-) (156). Neurocognitive diagnosis of HAND in life was assigned following 
administration of the neurocognitive test battery implemented by the NNTC according to the 
Frascati Criteria (145, 157). Among the 76 HIV+/HIVE- individuals, 37 subjects were diagnosed 
with HAND and 6 subjects were confirmed as neurocognitively normal. Among the 14 HIVE 
individuals, 9 subjects were diagnosed with HAND. The remaining 33 HIV+/HIVE- subjects and 5 
HIVE subjects had neurocognitive dysfunction in which factors other than HIV could not be ruled 
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out or had no associated neurocognitive diagnosis available. Among the 90 HIV+ subjects, 57 
subjects were ART-experienced, 15 subjects were ART-naïve, and ART status was unknown for 
18 subjects. On average, HIV+ subjects were 6.6 years younger than HIV- subjects but did not 
significantly differ from HIV- subjects in gender, ethnicity, race, or post-mortem interval. Additional 
demographic and clinical data of this cohort are summarized in Table 2.1. 
Isolation and culture of human primary fetal astrocytes 
Human primary fetal astrocyte cultures were prepared by the Basic Science Core I of the 
Comprehensive NeuroAIDS Center (CNAC) at Temple University School of Medicine. Fetal brain 
tissues (gestational age 16-18 weeks) obtained from elective abortion procedures were washed 
in Hank’s balanced salt solution (HBSS), meninges and blood vessels were removed, and tissues 
were mechanically disrupted then digested with 0.25% trypsin (Life Technologies) and 10U/mL 
DNASE I (Sigma-Aldrich). Single cell suspensions were plated in mixed glial growth media 
(Dulbecco’s modified eagle medium/Ham’s F-12 nutrient mixture with HEPES (DMEM/F-12, 
Gibco) supplemented with 10% FBS (HyClone), 50ug/mL Gentamicin (Gibco), 5ug/mL Fungizone 
(Gibco), 2mM L-glutamine (Gibco), and 10ug/mL Insulin (Sigma-Aldrich)) and maintained under 
10% CO2 for 5 days. To enrich for astrocytes, the mixed glial cell cultures were shaken at 200rpm 
for 14-18 hours, medium containing detached cells was removed, and the remaining adherent 
monolayers of astrocytes were fed with astrocyte growth media (DMEM/F-12 supplemented with 
15% FBS, 50ug/mL Gentamicin, 5ug/mL Fungizone, 2mM L-glutamine, and 10ug/mL insulin) and 
maintained at 37°C and 5% CO2. Cultures were maintained under these conditions at the 
University of Pennsylvania for at least 2 days prior to initiating experiments. 
U251 cell culture 
The human U251 MG glioma cell line (formerly known as U373 MG) was cultured in growth 
medium (DMEM (Gibco) supplemented with 10% FBS, 2mM L-glutamine, 10mM HEPES (Gibco), 
100U/mL penicillin, and 100µg/mL streptomycin (Gibco) and maintained at 37°C and 5% CO2. for 
at least 24 hours before initiating treatment. 
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Cell culture treatment conditions  
Stock solutions of purified lipopolysaccharide (LPS; Sigma-Aldrich), recombinant human TNFα 
(Peprotech), and recombinant human IFNγ (Peprotech) were prepared in sterile phosphate 
buffered saline (PBS). Cells were exposed to PBS vehicle, LPS (1µg/mL), TNFα (10ng/mL), and 
IFNγ (10ng/mL) alone or in combination for indicated lengths of time and medium and treatments 
were replaced every 3 days. Stock solutions of the cell-permeable proteasome inhibitor MG132 
(Sigma-Aldrich) were prepared in sterile DMSO and cells were treated with MG132 (5µM) 2 hours 
prior to and throughout pulse-chase assays to inhibit proteasome activity. 
Extraction of protein and RNA from dorsolateral prefrontal cortex (DLPFC) 
Fresh frozen brain tissue stored at -80°C was dissected on dry ice from Brodmann areas 8 or 9 to 
obtain DLPFC samples. Protein lysates were prepared from 100-500mg of tissue homogenized 
by silica bead beating and sonication in 3 volumes of buffer (10mM Tris-HCl pH 7.8, 0.5mM 
Dithiothreitol (DTT), 5mM MgCl2, 0.03% Triton X-100) containing protease inhibitor cocktail 
(Sigma-Aldrich) and phosphatase inhibitor cocktail set II (EMD Millipore). Total RNA was 
prepared from 100mg of adjacent DLPFC tissue using the RNeasy Lipid Tissue Mini Kit (Qiagen). 
Extraction of protein and RNA from cell cultures 
Protein lysates from cell cultures were prepared in buffer (75mM Tris-HCl (pH 6.8), 15% glycerol, 
3.75mM EDTA, and 3% SDS) supplemented with Complete Protease Inhibitor Cocktail (Roche 
Applied Science) and PhosSTOP Phosphatase Inhibitor Cocktail (Roche Applied Science) and 
samples were heated for 5-10 minutes at 95°C. Total RNA from cell cultures was prepared using 
the RNeasy Micro Kit (Qiagen). 
Western blot analysis  
Equivalent amounts of protein, measured using the Detergent Compatible (DC) protein assay 
(Bio-Rad), were added to Laemmli sample buffer (50mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 
12.5mM EDTA, 0.002% bromophenol blue) with 2.5% 2-Mercaptoethanol and denatured at 95°C 
for 5 minutes. Proteins were resolved by SDS-PAGE and subsequently transferred to 
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polyvinylidene fluoride (PVDF) membranes. For infrared fluorescent detection of proteins (all cell 
culture experiments and detection of HO-1, GAPDH, β-tubulin in DLPFC samples), membranes 
were blocked in Odyssey Blocking Buffer (LI-COR Biosciences) diluted with PBS for 1 hour at 
room temperature, incubated overnight at 4°C with primary antibodies diluted in Odyssey 
Blocking Buffer/PBS containing 0.1% Tween-20 (PBST), washed in PBST, and IRDye-conjugated 
secondary antibodies (LI-COR Biosciences) in Odyssey Blocking Buffer/PBST containing 0.004% 
SDS were applied for one hour at room temperature. Membranes were washed in PBST and 
scanned with the Odyssey CLx Infrared Imaging System (LI-COR Biosciences). For 
chemiluminescent detection of LMP7, PA28α, GAPDH, and βtubulin proteins in DLPFC samples, 
membranes were blocked in 5% nonfat dry milk in TBST for 1 hour at room temperature, washed 
with TBST, incubated overnight at 4°C with primary antibodies diluted in 5% milk/TBST, washed 
in TBST, and HRP-conjugated secondary antibodies (Jackson Immunoresearch) were applied for 
one hour at room temperature. After additional TBST washes, SuperSignal West enhanced 
chemiluminescent (ECL) substrate (Thermo Scientific) was applied and membranes were 
exposed to Kodak BioMAX XAR film. Primary and secondary antibodies used in Western blot are 
listed in Table 2.2 for DLPFC samples and Table 2.3 for cell culture samples. 
 
Background-corrected signal intensity of protein bands was determined using Image Studio Lite 
software (LI-COR Biosciences) or ImageJ software (NIH). Protein expression in DLPFC samples 
was normalized to GAPDH (LMP7, PA28α) or β-tubulin (HO-1, HO-2) and fold change was 
calculated relative to the average of the HIV-negative group. In all cell culture experiments, 
protein expression was normalized to β-tubulin and fold change was calculated relative to vehicle 
condition. 
Quantitative real-time PCR (qPCR) 
RNA purity and concentration was measured with NanoDrop 2000c UV-Vis spectrophotometer 
(Thermo Fisher Scientific) and 1µg of total RNA was reverse transcribed to single-stranded cDNA 
using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Relative RNA expression in 
DLPFC samples was determined by qpCR using 80ng cDNA, TaqMan Fast Universal PCR 
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Master Mix (Applied Biosystems), and TaqMan primer/probe sets (HMOX1:Hs01110250_m1; 
GAPDH: Hs0275899_g1; Applied Biosystems) in 20µL reaction volumes. Reactions were run in 
technical triplicate on the 7500 Fast Real-Time PCR System (Applied Biosystems). GAPDH was 
used as the reference gene and RNA expression was calculated for each sample relative to the 
average of the HIV-negative group using the ΔΔCq method. Relative RNA expression in cell 
culture samples was determined by qPCR using 50ng cDNA, RealMasterMix Probe (5Prime Inc.) 
and TaqMan primer/probe sets (HMOX1:Hs01110250_m1; HMOX2: Hs01558390_m1; βActin 
(ACTB): Hs01060665_g1; Applied Biosystems) in 20µL reaction volumes. Reactions were run in 
technical triplicate on a MasterCycler RealPlex 2 (Eppendorf). βActin was used as the reference 
gene and RNA expression was calculated relative to the corresponding vehicle condition using 
the ΔΔCq method. 
Immunoperoxidase histochemistry and immunofluorescence (IF) 
Immunohistochemical analyses of subcortical white matter tissue samples from HIV-positive and 
HIV-negative cases were performed by the Texas NeuroAIDS Research Center at the University 
of Texas Medical Branch. Archival paraffin-embedded tissue blocks were sectioned at 6µm 
thickness, placed onto glass slides, and rehydrated as described previously (144). Tissue 
sections used for IHC were quenched with 3% hydrogen peroxide in methanol and antigen 
retrieval was performed by irradiating with microwaves in sodium citrate buffer (10mM sodium 
citrate, 0.05% Tween-20, pH 6.0) for 10 minutes. Slides were blocked in 0.1% nonfat dry milk and 
1% normal goat serum and incubated overnight with primary antibody against LMP2 (see Table 
2.4). Biotinylated anti-rabbit secondary antibody (Vector Laboratories) was applied for one hour 
and staining was developed using Vectastain ABC and DAB peroxidase substrate kits (Vector 
Laboratories). In IF procedures, antigen retrieval was performed by steaming tissue sections in 
sodium citrate buffer for 20 minutes. Image-iT FX signal enhancer (Invitrogen Molecular Probes) 
was applied to slides for 30 min and slides were blocked in 5% bovine serum and 5% normal goat 
serum. Slides were incubated overnight with antibodies against immunoproteasome subunits and 
the astrocyte cytoskeletal protein GFAP (see Table 2.4). Species appropriate Alexa-Fluor 
fluorochrome conjugated secondary antibodies (Invitrogen Molecular Probes) were applied for 1 
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hour and autofluorescence was quenched with 1% Sudan Black B (Sigma-Aldrich) in 70% 
ethanol. Coverslips were mounted using Slow Fade Gold with DAPI (Invitrogen Molecular 
Probes). Images were acquired at the University of Texas Medical Branch (UTMB) using a Zeiss 
LSM 510 UV META laser scanning confocal microscope consisting of an Axiovert 200M Inverted 
Microscope equipped with Argon, dual HeNe, and UV lasers and fluorescence filters set for DAPI, 
FITC, and TRITC, a scanning module with visible and UV acousto optical tunable filters, two 
independent photomultiplier tubes (2 PMTs), and a 32-PMT array (Carl Zeiss MicroImaging, Inc.). 
Transient transfection of U251 cells 
U251 cells were plated to 10cm dishes in antibiotic-free growth media (DMEM supplemented with 
10% FBS, 2mM L-glutamine, and 10mM HEPES) 24 hours prior to starting treatment with 
10ng/mL IFNγ or vehicle. One day later, cells were transiently transfected with an expression 
plasmid containing the human HMOX1 open reading frame cDNA (NCBI accession number: 
NM_002133.2) fused to an N terminal FLAG tag and inserted into the pEZ-M11 mammalian 
expression vector (EX-V1697-M11, GeneCopoeia Inc) using Lipofectamine 3000 Reagent (Life 
Technologies). At 24 hours post-transfection, cells were replated to 35mm dishes coated with 
poly-D-lysine and maintained an additional 24 hours before being used in experiments. Once 
treatment was initiated, cells were continuously exposed to IFNγ or vehicle for the duration of 
experiments and treatment was replaced whenever medium was changed.  
Immunoprecipitation and detection of FLAG-HO-1 
Protein lysates for immunoprecipitation of FLAG-HO-1 protein were prepared by lysing cells in 
immunoprecipitation (IP) buffer (50mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, and 1% Triton X-
100) supplemented with Complete Protease Inhibitor Cocktail (Roche Applied Science), 
PhosSTOP Phosphatase Inhibitor Cocktail (Roche Applied Science), and 20mM iodoacetmide 
(Sigma-Aldrich) for 30 min on ice and lysates were spun at 12,000 x g for 15 minutes at 4°C.  
Equal amounts of protein from supernatant fractions were incubated with anti-FLAG M2 affinity 
gel (Sigma-Aldrich) overnight at 4°C to isolate FLAG-HO-1, beads were spun for 30 seconds at 
8,000 x g, washed 3 times in wash buffer (50mM Tris HCl pH 7.4, 150mM NaCl), resuspended in 
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2x sample buffer (125mM Tris HCl pH 6.8, 4% SDS, 20% glycerol, 0.004% bromophenol blue, 
and 10% 2-Mercaptoethanol), and bound protein was eluted from the beads by heating at 95°C 
for 5 minutes. Expression of FLAG-HO-1 protein was determined by fluorescent Western blot as 
described above, with the following modification. After blocking, membranes were incubated 
simultaneously with anti-FLAG primary antibody (Sigma-Aldrich) and IRDye 680RD Detection 
Reagent (LI-COR Biosciences) diluted in Odyssey Blocking Buffer/PBST containing 0.004% SDS 
for 1 hour at room temperature (see Table 2.3). The IRDye 680RD Detection Reagent only 
recognizes native IgG, preventing detection of denatured heavy and light IgG chains present in 
the immunoprecipitated samples. 
Pulse-chase assay 
U251 cells expressing FLAG-HO-1 and continuously exposed to IFNγ (or vehicle) for 72 hours 
were used in pulse-chase assays. Cells were treated with 5µM of the cell permeable proteasome 
inhibitor MG132 (or DMSO vehicle) for 2 hours, washed in HBSS, and starved for 25 minutes in 
labeling media (DMEM without L-glutamine/L-methionine/L-cystine (Corning) supplemented with 
3% dialyzed FBS (HyClone), 2mM L-glutamine, 1mM sodium pyruvate, and 10mM HEPES). Cells 
were then pulsed for 25 minutes with ~85µCi [35S]L-methionine/L-cysteine (Perkin Elmer) diluted 
into 1mL fresh labeling media, washed once with chase medium containing excess unlabeled L-
methionine/L-cysteine (DMEM supplemented with 10% FBS, 2mM L-Glutamine, 10mM HEPES, 
and 5mM each of L-methionine and L-cysteine (Calbiochem), and either immediately lysed (0 
hour) or incubated in fresh chase medium at 37°C, 5% CO2 for indicated times (2, 4, 8, 12 hours). 
Cells were continuously exposed to IFNγ, MG132, and appropriate vehicles throughout each pre-
treatment, starve, pulse, and chase period.  
 
At indicated time points, cells were lysed and FLAG-HO1 was immunoprecipitated according to 
the procedures described above, and eluted proteins were separated by SDS-PAGE. Dried gels 
were exposed overnight to a storage phosphor screen (Molecular Dynamics) and incorporation of 
35S in FLAG-HO-1 was detected by phosphorimaging with Typhoon FLA 7000 (GE Healthcare). 
Background-corrected signal intensity of bands was determined using Image Studio Lite (LI-COR 
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Biosciences). Signal intensity relative to 0 hour was calculated separately within each treatment 
condition and relative signal over time for each condition was combined from 3 independent 
biological replicates. 
Liquid scintillation counting of 35S 
The relative rate of total cellular protein degradation in pulse-chase experiments was determined 
using liquid scintillation counting of 35S-Met/Cys incorporated into intracellular protein. 
Supernatant fractions from each pulse-chase experiment were spotted (3µL in technical 
duplicate) onto filter paper (Whatman) and air dried. Proteins were precipitated by addition of ice 
cold 10% Trichloroacetic acid (TCA) to the filters for one hour at 4°C. Filters were washed with 
cold 70% ethanol to remove soluble material, allowed to dry completely, and then placed in 
scintillation vial with 5mL of Scintiverse BD cocktail (Fisher)  and counted for 35S in a liquid 
scintillation counter (Wallace LKB). 
Statistics 
All quantifications are expressed as mean ± standard error mean (SEM) and protein and RNA 
expression data were log transformed. In the DLPFC cohort, HIV subgroups were compared by 
one-way ANOVA followed by Holm-Sidak post-test and linear trends were analyzed by Pearson’s 
correlation with line of best fit determined by linear regression. In cell culture experiments, 
statistical comparisons of two groups were made by paired t-test and comparisons of three or 
more groups were made by repeated measures one-way ANOVA with Holm-Sidak post-test. Data 
from pulse-chase experiments was fit with one-phase exponential decay and extra sum of 
squares F test was used to compare the rate of decay (k). Effects of MG-132 were analyzed by 2-
way repeated measures ANOVA with Holm-Sidak post test. All statistical analyses were 
performed using GraphPad Prism 7 software (GraphPad Software). Significance was defined as 
*P <0.05, **P <0.01, ***P <0.001. 
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2.4 Results 
HO-1 protein loss is driven by a post-transcriptional mechanism in the DLPFC of HIV-infected 
individuals. 
To determine whether HIV-associated HO-1 protein loss occurs through similar mechanisms in 
cultured macrophages and in brain tissue, we measured HO-1 RNA expression in DLPFC tissue 
samples from HIV-infected individuals with and without HIV encephalitis (HIVE) (HIVE+, n=14 
and HIV+/HIVE-, n=75, respectively) and non-infected individuals (HIV-, n=66). HO-1 RNA 
expression was significantly increased in the DLPFC of HIV+/HIVE- individuals as compared to 
HIV- controls, and a further increase was evident in the HIVE+ subgroup (Fig. 2.1A). In contrast, 
we previously demonstrated that HO-1 protein expression was significantly reduced in both 
HIV+/HIVE- and HIVE+ individuals in comparison to HIV- individuals (Fig. 2.1B) (104). HO-1 
protein expression was negatively associated with HO-1 RNA expression in the DLPFC of HIV+ 
individuals (HIV+/HIVE- and HIVE+), but there was no association in HIV- individuals (Fig. 2.1C). 
The discordance between HO-1 protein and RNA expression in HIV+ brain suggests that HIV 
infection of the CNS drives reduced expression of HO-1 protein through a post-transcriptional 
mechanism. 
 
Induction of immunoproteasome subunits is associated with reduced HO-1 protein in the DLPFC 
of HIV-infected individuals. 
Post-transcriptional HO-1 protein loss could potentially result from decreased translation or 
enhanced degradation of HO-1 protein within HIV+ brain. As we previously identified increased 
expression of immunoproteasome subunits within the prefrontal cortex of HIV+ individuals, we 
hypothesized that HIV-driven induction of immunoproteasomes may increase the rate of HO-1 
degradation and ultimately lead to reduced HO-1 protein (144). We next examined associations 
between HO-1 RNA and protein with expression of immunoproteasome subunits LMP7 and 
PA28α, measured previously by Western blot, within our DLPFC cohort. HO-1 RNA was 
positively associated with both LMP7 (Fig. 2.2A) and PA28α (Fig. 2.2D) protein expression in 
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both HIV- and HIV+ groups. In contrast, HO-1 protein was negatively correlated with LMP7 (Fig. 
2.2B) and PA28α (Fig. 2.2E) only in the HIV+ group, suggesting that HO-1 protein loss and 
immunoproteasome induction may share a common mechanism that is driven by HIV-infection 
within the brain. As HO-2 protein was not significantly associated with LMP7 (Fig. 2.2C) or PA28α 
(Fig. 2.2F) expression in either group, it is likely that the relationship between immunoproteasome 
induction and HO-1 protein expression is relatively specific to the HO-1 isoform of heme 
oxygenase. 
 
Immunoproteasome subunit LMP2 is increased in HIV-infected subcortical white matter. 
Having established that reduced expression of HO-1 protein is associated with 
immunoproteasome induction in the DLPFC, to better understand mechanisms driving HO-1 
protein loss, we next examined which types of cells express immunoproteasome subunits in HIV+ 
brain. Previously, we observed increased immunoproteasome expression in both DLPFC and 
subcortical white matter tissues from HIV+ cases and localized these subunits to neurons using 
dual indirect immunofluorescence techniques (144). Using immunohistochemical and 
immunofluorescence techniques, we examined the expression of immunoproteasome subunit 
LMP2 in subcortical white matter tissue, as immunoproteasome immunoreactivity was generally 
more intense in white matter than in adjacent DLPFC tissue. LMP2 immunolabeling was 
increased in HIV+ white matter tissue compared to HIV- tissue samples as measured by 
immunohistochemistry (Fig. 2.3A) and indirect immunofluorescence (Fig. 2.3B). In HIVE tissue, 
LMP2 was observed within microglial nodules, suggesting that glial cells are a source of 
immunoproteasome expression within HIV+ brain. 
 
Immunoproteasome subunits are expressed in glial cells in HIVE subcortical white matter. 
To examine glial expression of immunoproteasome subunits, we performed dual 
immunofluorescence staining in HIVE white matter tissue using antibodies against the astrocyte 
specific cytoskeletal protein glial fibrillary acidic protein (GFAP), oligodendrocyte myelin 
27  
glycoprotein (OMG), and CD68 to identify astrocytes, oligodendrocytes, and 
macrophage/microglial cells, respectively. Double labeling with these glial markers and LMP2 
revealed the presence of this immunoproteasome subunit within astrocytes (Fig. 2.4A), 
oligodendrocytes (Fig 2.4B), and macrophage/microglia (Fig. 2.4C). Double labeling with PA28α 
similarly showed expression of this immunoproteasome in all of the glial cell types examined (Fig. 
2.5 A-C). These findings, together with previous work demonstrating immunoproteasome 
induction within neuronal cells of HIV+ brain tissue, suggest that immunoproteasomes are 
ubiquitously induced in the brain of HIV-infected individuals. 
 
Prolonged exposure to IFNγ reduces HO-1 protein, but not RNA, in human primary fetal 
astrocytes 
Although HIV infection of macrophages in vitro reduces HO-1 protein expression in macrophages, 
astrocytes do not support productive HIV infection. However astrocytes respond to various 
inflammatory stimuli associated with HIV infection, including TNFα, LPS, and IFNγ, and we 
hypothesized that HIV-relevant immune stimuli may drive HO-1 protein loss within astrocytes. 
Human primary human fetal astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and 
IFNγ (10ng/mL) alone or in combination for 15 days in order to model the chronic inflammatory 
state of HIV-infected individuals. As measured by quantitative real-time PCR, HO-1 RNA was not 
significantly changed after chronic exposure to any of the inflammatory stimuli (Fig. 2.6A). Less 
stringent statistical testing (paired t-test) revealed a trend for increased HO-1 RNA expression 
after exposure to IFNγ alone or in combination with TNFα or LPS (P < 0.05). Similarly, HO-2 RNA 
was significantly increased after exposure to IFNγ (Fig. 2.6B). IFNγ (alone or in combination with 
TNFα or LPS) significantly decreased HO-1 protein and significantly increased HO-2 protein, 
suggesting that IFNγ differentially regulates heme oxygenase isoforms (Fig. 2.6C, Fig. 2.6D, Fig. 
2.6E). NQO1, an ARE effector protein, was also increased by IFNγ (Fig. 2.6F). As IFNγ appeared 
to drive post-transcriptional HO-1 protein loss in astrocytes, we visualized the degree of 
concordance between protein and RNA expression by plotting each biological replicate grouped 
according to the absence (TNFα, LPS, TNFα + LPS) or presence of IFNγ (IFNγ, IFNγ + TNFα, 
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IFNγ + LPS). In the absence of IFNγ, TNFα and LPS led to changes in HO-1 RNA that were 
paralleled at the protein level, but exposure to IFNγ led to discordant protein and RNA expression 
as demonstrated by the clustering of IFNγ exposed samples in the lower right quadrant (Fig. 3G). 
In contrast, HO-2 protein and RNA expression was regulated in parallel after exposure to IFNγ, 
TNFα, and LPS (Fig. 3H). These data demonstrate that chronic exposure of human primary fetal 
astrocytes to IFNγ recapitulates the post-transcriptional HO-1 protein loss seen in HIV+ brain. 
 
Twenty-four hour exposure to IFNγ does not reduce HO-1 protein in astrocytes 
We next examined effects of the HIV-relevant inflammatory mediators after a 24 hour exposure in 
human primary fetal astrocytes to determine if IFNγ-driven HO-1 dysregulation occurs within a 
shorter time frame. None of the inflammatory stimuli significantly altered HO-1 (Fig. 2.7A) or HO-2 
(Fig. 2.7B) RNA expression after 24-hours of exposure. In contrast to the reduced HO-1 protein 
observed after 15 days of exposure, IFNγ did not significantly decrease HO-1 protein after 24 
hours of exposure (Fig. 2.7C, Fig. 2.7D), suggesting that IFNγ-driven HO-1 protein loss requires 
chronic exposure. HO-1 protein was induced by TNFα alone or in combination with LPS, but 
treatment with IFNγ in combination with TNFα blocked this induction (Fig. 2.7D). HO-2 protein 
was unchanged after 24 hours of exposure to the various inflammatory stimuli (Fig. 2.7E) but 
NQO1 protein was increased after exposure to TNFα, IFNγ, and TNFα + LPS (Fig. 2.7F), again 
suggesting that effects on HO-1 expression are relatively specific for this isoform and not likely 
driven by global ARE changes. 
 
Prolonged exposure to IFNγ induces immunoproteasome subunits at the expense of constitutive 
subunits in astrocytes 
Given that 15-day exposure of astrocytes to IFNγ recapitulated the post-transcriptional HO-1 
protein loss seen in HIV+ brain, we next examined expression of the immunoproteasome 
regulatory subunit PA28α, the immunoproteasome catalytic subunits LMP2 and LMP7, and the 
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constitutive catalytic subunits β1, β2, and β5 in human primary fetal astrocytes after 15 days of 
exposure to inflammatory stimuli (Fig. 2.8A). Expression of PA28α protein was significantly 
increased after exposure to TNFα, IFNγ, IFNγ + TNFα, and IFNγ + LPS (Fig. 2.8B), while the 
catalytic immunoproteasome subunits LMP7 (Fig. 2.8C) and LMP2 (Fig. 2.8E) were increased by 
all of the inflammatory stimuli tested. Induction of immunoproteasome subunits was greatest in 
the presence of IFNγ as compared to conditions in which IFNγ was absent (comparisons between 
groups by RM-ANOVA with post hoc Holm-Sidak test, P < 0.01). In contrast to enhanced 
expression of immunoproteasome subunits, constitutive catalytic subunits β5 (Fig. 2.8C), β2 (Fig. 
2.8D), and β1 (Fig. 2.8E) were significantly reduced after exposure to IFNγ (alone or in 
combination with TNFα, LPS). Interestingly, induction of immunoproteasome subunits without 
concurrent loss of constitutive subunits, as occurred after chronic exposure to TNFα, does not 
reduce HO-1 protein expression (Fig. 2.6D). Replacement of constitutive subunits by 
immunoproteasome subunits appears to be necessary for HO-1 protein loss in astrocytes, as 
reduced HO-1 was only observed after exposure to IFNγ and in association with a near complete 
loss of constitutive proteasome subunits (Fig. 2.6D, Fig. 2.8A). 
 
Biphasic regulation of HO-1 protein by IFNγ is associated with replacement of constitutive 
proteasomes by immunoproteasomes. 
Given the critical role of IFNγ in driving HO-1 protein loss in astrocytes, we next examined effects 
across 6 logs of IFNγ concentrations that included concentrations reported in the CSF of HIV+ 
individuals (2-10pg/mL)(54). Human primary fetal astrocytes were exposed to IFNγ for 15 days 
and protein expression was determined by Western blot (Fig. 2.9A). HO-1 protein exhibited a 
biphasic response to chronic IFNγ - HO-1 protein was increased beginning at 10pg/mL and 
continuing up to 100pg/mL (Fig. 2.9B). However at 1ng/mL IFNγ, there was a significant decrease 
in HO-1 protein compared to the previous dose of 100pg/mL and at higher doses HO-1 was 
significantly decreased compared to vehicle (Fig. 2.9B). In contrast, biphasic regulation was not 
observed for either HO-2 (Fig. 2.9C) or NQO1 (Fig. 2.9D) proteins and instead, IFNγ led to 
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increased expression at higher concentrations. Immunoproteasome subunits PA28α (Fig. 2.9E), 
LMP7 (Fig. 2.9G), and LMP2 (Fig. 2.9H) were significantly increased after prolonged exposure to 
IFNγ concentrations of 10pg/mL and higher. The constitutive catalytic subunits β2 (Fig. 2.9F), β5 
(Fig. 2.9G), and β1 (Fig. 2.9H) were significantly reduced at IFNγ concentrations of 1ng/mL and 
higher. Interestingly, the transition between 100pg/mL and 1ng/mL IFNγ was the point at which 
HO-1 protein began to decrease and was associated both with significantly greater induction of  
immunoproteasome subunits and with significantly greater loss of constitutive proteasome 
subunits. These data provide additional evidence that replacement of constitutive proteasomes by 
immunoproteasomes is critical for IFNγ-driven HO-1 protein loss. 
 
IFNγ-driven HO-1 protein loss is associated with induction of immunoproteasomes and 
progressive loss of constitutive proteasomes over time 
We next examined the effects of IFNγ over time in human primary fetal astrocytes exposed to 
IFNγ (10ng/mL) or vehicle for 3, 6, 9, 12 and 15 days. IFNγ induced HO-1 RNA expression in a 
time-dependent manner, with significantly increased expression observed at days 9, 12 and 15 
(Fig. 2.10A). In contrast, induction of HO-2 RNA occurred earlier, with significantly increased 
expression observed at days 3, 9, 12, and 15 of IFNγ exposure (Fig. 2.10B). In agreement with 
our earlier results, HO-1 protein was significantly reduced in astrocytes exposed to IFNγ for 15 
days, despite the persistent elevation in HO-1 RNA occurring in IFNγ exposed cells (Fig. 2.10C, 
Fig 2.10D). The discordant effect of IFNγ on RNA and protein expression was relatively specific to 
HO-1, as HO-2 expression was similarly induced at both RNA and protein levels throughout the 
course of IFNγ exposure (Fig. 2.10B, Fig. 2.10C, Fig. 2.10E). Furthermore, NQO1 protein was 
significantly increased at days 9, 12 and 15, which again suggests that HO-1 protein deficiency at 
day 15 is not likely driven by global effects on the ARE (Fig. 2.10F). Immunoproteasome subunits 
PA28α (Fig. 2.10G), LMP7 (Fig. 2.10I), and LMP2 (Fig. 2.10J) were increased at each time point, 
with a significantly greater induction of LMP7 and LMP2 evident on day 6 as compared to day 3. 
The constitutive subunits β2 (Fig. 2.10H), β5 (Fig. 2.10I), and β1 (Fig. 2.10J) were significantly 
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reduced at each of the time points. There was a progressive time-dependent loss of β5 (Fig. 
2.10I) and β1 (Fig. 2.10J), as significantly greater reductions were evident at each time point as 
compared to the previous time point. These data provide further support that IFNγ-driven loss of 
HO-1 protein requires replacement of constitutive proteasomes by immunoproteasomes. 
 
IFNγ increases the rate of HO-1 protein degradation mediated by proteasome-dependent 
mechanisms 
Given the strong association between reduced HO-1 protein and induction of 
immunoproteasomes, we hypothesized that HO-1 protein is degraded more rapidly by 
immunoproteasomes than constitutive proteasomes. To examine this possibility, we performed 
pulse chase assays to measure the rate of HO-1 protein degradation after IFNγ exposure. For 
technical reasons, pulse chase experiments were performed in the U-251 cell line that was 
originally derived from a human glioblastoma astrocytoma. We first examined effects of IFNγ on 
HO-1, HO-2, and proteasome subunit expression to ensure that this cell line appropriately models 
astrocytes. After 3-day exposure to IFNγ, HO-1 and HO-2 RNA expression was significantly 
increased in U-251 cells (Fig. 2.11A). Expression of HO-2 protein was also increased by IFNγ 
while HO-1 protein was significantly reduced (Fig. 2.11B, 2.11C). Additionally, IFNγ increased 
expression of immunoproteasome subunits LMP7 and LMP2 and decreased expression of the 
corresponding constitutive β5 and β2 subunits (Fig. 2.11B, 2.11D). The discordance between 
RNA and protein levels observed for HO-1, but not HO-2, and the shift to expression of 
immunoproteasomes after IFNγ exposure in this cell line recapitulates the effects of prolonged 
IFNγ observed in human primary fetal astrocytes, thus supporting our choice of this cell line for 
further studies.  
 
We next determined the degradation rate of HO-1 in U-251 cells transiently expressing FLAG-
HO1 and exposed to IFNγ for 3 days (Fig. 2.12A, 2.12B). Pulse chase experiments demonstrated 
that IFNγ significantly increased the rate of FLAG-HO-1 degradation and reduced the measured 
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half-life from approximately 14 hours to 7.7 hours after IFNγ exposure (Fig. 2.13B, 2.13C). In 
contrast, IFNγ did not alter the rate of total cellular protein degradation as measured by liquid 
scintillation counting of TCA-precipitable lysates, suggesting that the increased rate of HO-1 
protein degradation is relatively specific and not due to a gross increase in cellular protein 
degradation (Fig 2.13C). As protein degradation can occur through several cellular pathways, we 
also examined the contribution of proteasome-dependent degradation by pre-treating cells with 
MG-132, a potent inhibitor of proteasome activity. MG-132 significantly increased the amount of 
[35S] labeled FLAG-HO1 protein remaining at each time point in both vehicle and IFNγ conditions 
(Fig. 2.13B, 2.13C), suggesting that the HO-1 degradation we measured is mediated, at least in 
part, by proteasome activity. These data demonstrate that HO-1 protein is degraded more rapidly 
in cells exposed to IFNγ and strongly implicate immunoproteasomes as the source of enhanced 
HO-1 protein degradation. 
 
2.5 Discussion 
The introduction and widespread use of ART has significantly altered the clinical course of HIV 
infection, transforming what was once a rapidly lethal disease into a manageable chronic 
condition, but HAND persist in a significant proportion of ART-treated individuals and represent a 
substantial clinical challenge for the management of HIV infection (31, 148, 158, 159). Despite 
abundant evidence implicating persistent inflammation and oxidative stress in the pathogenesis of 
HAND, the molecular mechanisms by which these processes drive neurocognitive impairment in 
HIV-infected individuals remain incompletely understood thus limiting the development of novel 
therapeutic approaches with neuroprotective benefit (58, 86, 160). We previously identified HO-1 
as both a potential host factor contributing to HIV-mediated neurocognitive impairment and as a 
promising therapeutic target for adjunctive neuroprotection in ART-treated HIV-infected 
individuals and in the current work describe a novel mechanism of HO-1 regulation that is driven 
by IFNγ (104). Our data demonstrate that HO-1 protein loss in HIV-infected brain is regulated by 
a post-transcriptional mechanism and we have recapitulated this effect in primary human 
astrocytes chronically exposed to IFNγ in vitro. In HIV-infected brain and in human astrocytes 
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exposed to IFNγ, these effects on HO-1 were relatively specific, as we did not observe similarly 
discordant expression of HO-2 RNA and protein and expression of NQO1 protein, another 
member of the ARE-driven gene family, was not reduced. Furthermore, we show that enhanced 
degradation of HO-1 protein by immunoproteasome complexes within astrocytes is a plausible 
mechanism mediating HO-1 protein loss and we have identified IFNγ as the critical driver of this 
process within the CNS of HIV-infected individuals. 
 
In contrast to our previous observation of reduced expression of HO-1 in the prefrontal of HIV-
infected individuals, HO-1 RNA expression is increased in these same individuals and HO-1 RNA 
expression is negatively associated with HO-1 protein expression within prefrontal cortex of HIV-
infected individuals. The lack of a significant association in HIV-negative individuals suggests that 
loss of HO-1 protein in the brain is likely mediated by a post-transcriptional mechanism 
dependent on HIV infection. TNFα, LPS, and IFNγ are potent immune activators associated with 
HIV infection and modulate the expression of HO-1 after acute exposure in various cell types, 
although effects on HO-1 after prolonged exposure have not been clearly defined (161, 162). 
Additionally, levels of TNFα, LPS, and IFNγ are increased in peripheral and central compartments 
of HIV-infected individuals and have been associated with HAND, suggesting chronic exposure to 
these immune activators as a potential mechanism by which HIV infection reduced HO-1 protein 
expression within the brain (64, 65, 72, 73). The post-transcriptional loss of HO-1 protein 
observed in brain was recapitulated in human primary fetal astrocytes following prolonged (15-
day) exposure to IFNγ, but HO-1 expression was not similarly regulated by prolonged exposure to 
TNFα or LPS alone or in combination with one another or by acute exposure to the various 
immune activators, suggesting that IFNγ modulates HO-1 expression through a mechanism that 
requires prolonged exposure and is not in common with TNFα or LPS. During HIV infection, 
elevations in IFNγ and neopterin, an indirect measure of IFNγ activity produced by macrophages 
and T cells, are evident in the serum, cerebrospinal fluid (CSF), and brain parenchyma even in 
individuals treated with ART and increased IFNγ was reported to be among the top three CSF 
biomarkers differentiating aviremic HIV-infected individuals from non-infected individuals (54, 60-
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62, 163). We previously showed that prefrontal cortex HO-1 protein loss is not associated with 
plasma viral load or use of ART and is thus likely driven by indirect effects of HIV infection that 
persist in individuals on suppressive ART regimens, highlighting an especially relevant role for 
persistently elevated IFNγ in mediating reduced expression of HO-1 protein in the brain (104).  
 
HIV-infection is associated with enhanced expression of immunoproteasome subunits within the 
brain and this is likely mediated by IFNγ, which plays a critical role in the host response to viral 
infection through the induction of immunoproteasome complexes which enhance the processing 
of antigens suitable for presentation on Major Histocompatability Complex Class I (MHC I) 
molecules (144, 164, 165). Induction of immunoproteasome subunits associated with reduced 
HO-1 protein in human primary fetal astrocytes following prolonged exposure to IFNγ and in the 
DLPFC of HIV-infected individuals where astrocytes within adjacent white matter were identified 
as a cellular source of immunoproteasome subunit expression. In vitro, induction of 
immunoproteasome catalytic subunits and concurrent loss of the corresponding constitutive 
catalytic proteasome subunits appears to be necessary to drive reduced expression of HO-1 
protein, given that conditions which increase expression of immunoproteasome subunits without 
reducing expression of constitutive proteasome subunits are not associated with reduced HO-1 
protein expression. This apparent requirement for concurrent induction of immunoproteasomes 
and loss of constitutive proteasomes immunoproteasomes implies that the functional balance 
between activities of constitutive and immunoproteasome complexes is an important determinant 
of effects on HO-1 expression. The extent to which constitutive proteasomes are replaced by 
immunoproteasomes within HIV-infected brain is not yet clear, but the increased expression of 
immunoproteasome subunits we have observed is likely to represent a functionally important shift 
favoring immunoproteasome complexes given the HO-1 protein loss observed in HIV-infected 
brain.  
 
Within the brain, expression of immunoproteasome subunits was significantly associated with 
HO-1 RNA in both HIV-infected and non-infected individuals, but only in HIV-infected individuals 
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was a significant (inverse) association between expression of immunoproteasome subunits and 
HO-1 protein observed. This suggests that IFNγ regulates HO-1 RNA and HO-1 protein through 
distinct mechanisms. Our in vitro experiments provide evidence that IFNγ promotes induction of 
HO-1 RNA expression in a relatively consistent manner across time and concentrations, but 
dramatically shifting the balance to favor immunoproteasomes and associated HO-1 protein loss 
requires a persistent exposure to sufficiently high levels of IFNγ. When we assessed effects of 
prolonged exposure to IFNγ across a range of doses, there was a clear divergence in the effect 
on HO-1 expression as doses ≤100pg/mL induced expression of HO-1 protein while doses 
≥1ng/mL had an opposite effect and progressively reduced expression of HO-1 protein. 
Interestingly, these two doses of IFNγ also mark a critical point for divergent effects on 
expression of proteasome subunits as doses ≥1ng/mL IFNγ induce immunoproteasome subunits 
and concurrently reduce constitutive proteasome subunits while lower doses induce 
immunoproteasome subunits but do not significantly reduce constitutive subunits. Across time, 
IFNγ progressively induces HO-1 RNA expression and HO-1 RNA is significantly increased at 
days 9, 12, and 15. In contrast, IFNγ does not significantly alter HO-1 protein until day 15, at 
which point HO-1 protein is reduced despite significantly elevated levels of HO-1 RNA. 
Immunoproteasome subunits are induced early at day 3 and exhibit further induction on day 6 
that is maintained through day 15, while a time-dependent and progressive loss of constitutive 
proteasome subunits occurs over the course of 15-days. The timing of HO-1 protein reduction 
suggests that a functional shift to immunoproteasome activity is required for IFNγ-driven HO-1 
protein loss, as the near complete loss of constitutive proteasome subunits by day 15 strongly 
implicate immunoproteasome activity as the main source of cellular proteasome activity at this 
time point.  
 
Our pulse-chase studies demonstrated that HO-1 protein is degraded more rapidly in cells 
exposed to IFNγ and inhibition of this degradation by the proteasome inhibitor MG-132 indicates 
that proteasome activity is mediating the degradation of HO-1 activity. The reduction in HO-1 
protein half-life driven by IFNγ is likely mediated by immunoproteasome complexes, given that 
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immunoproteasome subunits are induced and constitutive subunits are reduced in this condition, 
but contribution of constitutive proteasomes can not be completely ruled out because MG-132 
inhibits activity of both immunoproteasome and constitutive proteasome complexes.  
 
Our studies provide compelling evidence that enhanced degradation of HO-1 by 
immunoproteasomes within astrocytes drives HO-1 protein dloss in HIV-infected brain and 
suggests that persistently elevated IFNγ is a critical modulator linking chronic immune activation 
to HAND. When present at moderate levels and/or for brief periods, IFNγ may exert beneficial 
effects during HIV infection through induction of HO-1 expression, which would be expected to 
limit inflammation and oxidative stress in various tissues and to reduce neurotoxic secretions from 
HIV-infected macrophages/microglia within the CNS. Similarly, IFNγ-mediated induction of 
immunoproteasomes is likely a beneficial response that protects cells from proteotoxic stress and 
enhances capacity to degrade oxidatively damaged proteins that accumulate as a result of 
inflammation and oxidative stress (116). Persistently elevated IFNγ leads to a sustained induction 
of immunoproteasomes that potentially has deleterious effects in addition to reducing HO-1 
protein. Immunoproteasomes are designed to be a rapid and transient response, exhibiting a 
faster rate of assembly and significantly shorter half-life than constitutive proteasomes (131). 
Prolonged induction of immunoproteasomes may dysregulate the expression and/or degradation 
of cellular proteins other than HO-1 which could contribute to pathological processes. Studies 
suggest that immunoproteasomes enhance the production and presentation of antigenic peptides 
derived from myelin basic protein (MBP), suggesting similar effects on other endogenous proteins 
could contribute pathogenic processes (166-168).  
 
Development of HO-1 inducing therapies is a promising therapeutic approach for neuroprotection 
in ART-treated HIV-infected individuals. Modulation of HO-1 expression in HIV-infected 
macrophages was previously shown by our group to regulate extracellular glutamate and a 
similar function role of HO-1 is likely to exist within astrocytes, which are a critical regulator of 
glutamate homeostasis within the brain (104). Therapeutic induction of HO-1 may potentially 
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target multiple processes that contribute to the pathogenesis of HAND including inflammation, 
oxidative stress, and excitotoxic damage to neurons mediated by glutamate. A particularly 
attractive candidate is dimethyl fumarate (DMF), a CNS penetrant HO-1 inducer that is FDA 
approved for the treatment of multiple sclerosis. In addition to inducing HO-1 expression, DMF 
exerts numerous antioxidant and immunomodulatory effects that may be beneficial for ART-
treated HIV-infected individuals (169).  
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Table 2.1 Demographic and clinical data of subjects in the DLPFC cohort used for analysis 
of protein and RNA expression. 
Data are presented as mean ± standard deviation (SD) or as population percentages (%).  
Abbreviations: HIV encephalitis (HIVE), cerebrospinal fluid (CSF), HIV-associated neurocognitive 
disorders (HAND), antiretroviral therapy (ART). Statistical analyses: § Analysis of Variance; † 
Chi-square Test; ¶ Student’s t-test. 
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Table 2.2 Primary and secondary antibodies used for Western blotting in DLPFC tissues. 
Abbreviations: chemiluminescent (C); fluorescent (F); monoclonal antibody (mAb); polyclonal 
antibody (pAb). 
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Table 2.3 Primary and secondary antibodies used for Western blotting in cell cultures. 
Reagents used in immunoprecipitation experiments. Abbreviations: monoclonal antibody (mAb); 
polyclonal antibody (pAb). 
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Table 2.4 Primary antibodies used for IHC and IF in subcortical white matter tissue. 
Abbreviations: Immunofluorescence (IF); immunoperoxidase histochemistry (IHC); monoclonal 
antibody (mAb); polyclonal antibody (pAb). 
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2.6 Figures 
 
Figure 2.1 HO-1 RNA is increased in the DLPFC of HIV-infected subjects and correlates 
with reduced HO-1 protein. 
HO-1 RNA and protein expression in post-mortem DLPFC tissue samples was measured by 
qPCR and Western blot. (A) HO-1 RNA was measured in 66 HIV-, 75 HIV+/HIVE-, and 14 HIVE+ 
subjects, normalized to GAPDH, and expression relative to the mean HIV- group was calculated. 
(B) HO-1 protein expression was measured in 66 HIV-, 76 HIV+/HIVE-, and 14 HIVE+ subjects 
and normalized to βtubulin. Data were log transformed and the mean HIV- group expression was 
set to 0 (represented by black dotted line). Blue lines represent mean ± SEM. Groups were 
analyzed by one-way ANOVA with post hoc Holm-Sidak test. *P < 0.05, **P < 0.01, ***P < 0.001. 
(C) Associations between HO-1 RNA and HO-1 protein were determined in 65 HIV- and 89 HIV+ 
(75 HIV+/HIVE-, 14 HIVE+) subjects by Pearson’s correlation with line of best fit determined by 
linear regression. P < 0.05 considered significant. 
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Figure 2.2 Immunoproteasome induction correlates with reduced HO-1 protein in the 
DLPFC of HIV-infected subjects. 
Protein expression of HO-2 and immunoproteasome subunits LMP7 and PA28α was previously 
measured by Western blot within the DLPFC cohort. Correlations between (A, D) HO-1 RNA and 
(A) LMP7 and (D) PA28a protein were assessed in 64 HIV- and 87 HIV+ (73 HIV+/HIVE-, 14 
HIVE+) subjects. Correlations between (B, E) HO-1 protein and (B) LMP7 and (E) PA28a protein 
and between (C, F) HO-2 protein and (C) LMP7 and (F) PA28a protein were assessed in 65 HIV- 
and 88 HIV+ (74 HIV+/HIVE-, 14 HIVE+) subjects. Data were log transformed and the mean HIV- 
group expression was set to 0 (represented by black dotted line). Associations were determined 
by Pearson’s correlation with line of best fit determined by linear regression. P < 0.05 considered 
significant.  
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Figure 2.3 Immunoproteasome subunit LMP2 is increased within subcortical white matter 
of HIV-infected subjects. 
Subcortical white matter tissues from HIV- (black) and HIV+ (pink) cases were immunolabeled 
with LMP2 antibody and expression was assessed by (A) immunoperoxidase histochemistry and 
(B) indirect immunofluorescence (green: LMP2). Scale bar = 200µm. 
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Figure 2.4 LMP2 is expressed by glial cells in subcortical white matter of HIVE+ subjects. 
Subcortical white matter tissues from HIVE+ cases were immunolabeled with LMP2 and glial 
markers and colocalization was assessed by dual indirect immunofluorescence. Glial expression 
of LMP2 (green) was determined using antibodies against (A) GFAP, (B) OMG, and (C) CD68 
(red) to label astrocytes, oligodendrocytes, and macrophages/microglia, respectively. Scale bar = 
10µm. 
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Figure 2.5 PA28α is expressed by glial cells in subcortical white matter of HIVE+ subjects. 
Subcortical white matter tissues from HIVE+ subjects were immunolabeled with PA28α and glial 
markers and colocalization was assessed by dual indirect immunofluorescence. Glial expression 
of PA28α (green) was determined using antibodies against (A) GFAP, (B) OMG, and (C) CD68 
(red) to label astrocytes, oligodendrocytes, and macrophages/microglia, respectively. Scale bar = 
10µm. 
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Figure 2.6 15-day exposure to IFNγ induces post-transcriptional HO-1 protein loss in 
human primary astrocytes. 
Human primary fetal astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ 
(10ng/mL) alone or in combination for 15 days and medium and treatments were replaced every 
3 days. RNA and protein expression was measured by qPCR and Western blot. (A) HO-1 and (B) 
HO-2 RNA expression was quantified relative to vehicle after normalization to βActin. (C) 
Representative Western blot from a single biological replicate. (D) HO-1, (E) HO-2, and (F) NQO1 
protein expression was quantified relative to vehicle after normalization to βtubulin. Data were log 
transformed and the mean vehicle expression was set to 0 (dotted line). Bars represent mean ± 
SEM (n= 4 biological replicates). Statistical comparisons to vehicle were made by repeated 
measures ANOVA (RM-ANOVA) with post hoc Holm-Sidak test. *P < 0.05, **P < 0.01, ***P < 
0.001. Log transformed RNA and protein expression data relative to vehicle (set to 0, dotted 
lines) for (G) HO-1 and (H) HO-2 were individually plotted for each of n=3 biological replicates. 
The -IFNγ group (gray symbols) represent data from cells exposed to TNFα, LPS, and TNFα + 
LPS. The +IFNγ group (red symbols) represent data from cells exposed to IFNγ, IFNγ + TNFα, 
and IFNγ + LPS. 
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Figure 2.7 24-hour exposure to HIV-associated immune activators does not decrease HO-1 
protein in human astrocytes. 
Human primary fetal astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ 
(10ng/mL) alone or in combination for 24 hours and RNA and protein expression was measured 
by qPCR and Western blot. (A) HO-1 and (B) HO-2 RNA expression was quantified relative to 
vehicle after normalization to βActin. (C) Representative Western blot from a single biological 
replicate. (D) HO-1, (E) HO-2, and (F) NQO1 protein expression was quantified relative to vehicle 
after normalization to βtubulin. Data were log transformed and the mean vehicle expression was 
set to 0 (dotted line). Bars represent mean ± SEM (n= 4 biological replicates). Statistical 
comparisons were made by RM- ANOVA (RM-ANOVA) with post hoc Holm-Sidak test. *P < 0.05, 
***P < 0.001 vs. vehicle; ###P < 0.001 for indicated comparison. 
49  
 
Figure 2.8 15-day exposure to IFNγ induces immunoproteasomes and concurrently 
decreases constitutive proteasomes in human astrocytes. 
Human primary fetal astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ 
(10ng/mL) alone or in combination for 15 days and medium and treatments were replaced every 
3 days. Protein expression of immunoproteasome (LMP2, LMP7, PA28α) and constitutive 
proteasome (β1, β2, β5) subunits was measured by Western blot. (A) Representative Western 
blot from a single biological replicate. (B) PA28α, (C) LMP7 and β5, (D) β2, and (E) LMP2 and β1 
protein expression was quantified relative to vehicle after normalization to βtubulin. Solid lines 
represent mean ± SEM (n= 4 biological replicates). Data were log transformed and the mean 
vehicle expression was set to 0 (dotted line). Solid lines (immunoproteasome- purple; constitutive 
proteasome- black) represent mean ± SEM (n= 4 biological replicates). Statistical comparisons to 
vehicle were made by RM ANOVA with post hoc Holm-Sidak test. *P < 0.05, ***P < 0.001. 
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Figure 2.9 IFNγ-driven HO-1 protein loss is associated with loss of constitutive 
proteasomes and induction of immunoproteasomes in human astrocytes. 
Human primary fetal astrocytes were exposed to IFNγ (0.1pg/mL – 25ng/mL) for 15 days, 
medium and treatments were replaced every 3 days, and protein expression was measured by 
Western blot. (A) Representative Western blot from a single biological replicate. (B) HO-1, (C) 
HO-2, (D) NQO1, (E) PA28α, (F) β2, (G) LMP7 and β5, and (H) LMP2 and β1 protein expression 
was quantified relative to vehicle after normalization to βtubulin. Solid lines represent mean ± 
SEM (n= 4 biological replicates). Data were log transformed and the mean vehicle expression 
was set to 0 (dotted line). Solid lines (immunoproteasome- purple; constitutive proteasome- 
black) represent mean ± SEM (n= 4 biological replicates). Statistical comparisons to vehicle were 
made by RM ANOVA with post hoc Holm-Sidak test. * P < 0.05, ** P < 0.01, *** P < 0.001. 
Statistical comparisons between consecutive IFNγ doses were made by RM ANOVA with post 
hoc Holm-Sidak test. #P < 0.05, ##P < 0.01, ###P < 0.001. 
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Figure 2.10 IFNγ-driven HO-1 protein loss is associated induction of immunoproteasomes 
and progressive loss of constitutive proteasomes over time. 
Human primary fetal astrocytes were exposed to IFNγ (10ng/mL) and collected or provided with 
fresh medium and treatments every 3 days over a period of 15 days. RNA and protein expression 
was measured by qPCR and Western blot (A) HO-1 and (B) HO-1 RNA expression was 
quantified relative to vehicle after normalization to βActin. (C) Representative Western blot from a 
single biological replicate. (D) HO-1, (E) HO-2, (F) NQO1, (G) PA28α, (H) β2, (G) LMP7 and β5, 
and (H) LMP2 and β1 protein expression was quantified relative to vehicle after normalization to 
βtubulin. Solid lines represent mean ± SEM (n= 4 biological replicates). Data were log 
transformed and the mean vehicle expression was set to 0 (dotted line). Solid lines 
(immunoproteasome- purple; constitutive proteasome- black) represent mean ± SEM (n= 3-5 
biological replicates). Statistical comparisons to vehicle at each time point were made by paired t-
test. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical comparisons between consecutive time points 
were made by RM ANOVA with post hoc Holm-Sidak test. ##P < 0.01, ###P < 0.001. 
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Figure 2.11 IFNγ drives post-transcriptional HO-1 protein loss and immunoproteasome 
induction in the U251 cell line. 
U251 cells were exposed to IFNγ (10ng/mL) for 3 days and RNA and protein expression was 
measured by qPCR and Western blot. (A) HO-1 and HO-2 RNA expression was quantified 
relative to vehicle after normalization to βActin. (B) Representative Western blot from a single 
biological replicate. (C) HO-1, HO-2 and (D) LMP7, β5, LMP2, and β1 protein expression was 
quantified relative to vehicle after normalization to βtubulin. Data were log transformed and the 
mean vehicle expression was set to 0 (dotted line). Bars represent mean ± SEM (n= 3-4 
biological replicates). Statistical comparisons to vehicle were made by paired t-test. *P < 0.05, **P 
< 0.01. 
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Figure 2.12 U251 cells express FLAG-HO-1 protein 48 hours after transient transfection. 
U251 cells exposed to IFNγ (10ng/mL) for 24 hours were transiently transfected with an N-
terminal tagged FLAG-HO-1 expression plasmid, maintained in the presence of IFNγ, and 
collected on day 3 of exposure IFNγ (48 hours post-transfection). (A) Expression of FLAG-HO-1 
(black arrows) and endogenous HO-1 (blue arrow) was assessed in whole cell lysates by 
Western blot. Membrane probed with anti-HO-1 antibody is shown at two intensities to depict both 
FLAG-HO-1 (light) and endogenous HO-1 (dark). (B) FLAG-HO-1 was isolated by 
immunoprecipitation with anti-FLAG affinity gel and whole cell lysate inputs (10%) and FLAG-
bound fractions were assessed by Western blot to confirm efficient pull-down. 
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Figure 2.13 IFNγ significantly increases the rate of proteasome-dependent HO-1 
degradation. 
U251 cells transiently expressing FLAG-HO-1 and exposed to IFNγ (10ng/mL) for 3 days were 
used in pulse chase assays to measure HO-1 degradation. Cells were pulse labeled with 
[35S]methionine/cysteine and chased for indicated time points. Degradation mediated by 
proteasome activity was assessed by treating cells 2 hours prior to labeling with the proteasome 
inhibitor MG-132 (5µM) or DMSO (vehicle). (A) Intracellular protein degradation was determined 
by [35S] liquid scintillation counting of TCA-precipitable lysate fractions. Radioactivity was 
measured as counts per minute (CPM) and are expressed as a percentage relative to time 0 
within each independent experiment (n=3). Data represent mean ± SEM. Statistical analysis of 
treatment conditions at each time point was performed by two-way RM-ANOVA with post-hoc 
Holm-Sidak test. (B) Representative phosphorimage from a single experiment. Black arrows 
indicate radiolabeled FLAG-HO-1. (C) Degradation of HO-1 protein was determined by 
densitometric quantification of radiolabeled FLAG-HO-1 and are expressed as a percentage 
relative to time 0 within each independent experiment (n=3). Data represent mean ± SEM. 
Protein half-life in vehicle and IFNγ conditions (closed circles) was determined by one-phase 
exponential decay and rate of decay (k) was compared by Extra sum of squares F test. ***P < 
0.001. The effects of MG-132 at each time point was analyzed by two-way RM-ANOVA with post 
hoc Holm-Sidak test (significance not shown in figure). IFNγ vs. IFNγ+MG-132: P < 0.001 at all 
time points. PBS vs. PBS + MG-132: P < 0.01 at 8hr; P < 0.001 at 2, 4, and 12 hr.  
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3.1 Abstract 
The cytoprotective enzyme heme oxygenase-1 (HO-1) is rapidly induced in response to 
numerous cellular insults and plays a critical role in limiting inflammation and oxidative stress. We 
previously identified a significant loss of HO-1 protein expression in HIV-infected brain that 
associated with increased expression of HO-1 RNA. Contrastingly, in vitro HIV infection of 
monocyte derived macrophages (MDM) results in significant deficiency of HO-1 protein and HO-1 
RNA. In the previous chapter, we identified an IFNγ-driven mechanism of HO-1 protein loss within 
astrocytes that is associated with enhanced proteasome-dependent degradation of HO-1 protein. 
These data suggest that reduced expression of HO-1 driven by HIV infection and immune 
activators is mediated by different mechanisms and may be cell-type specific. To further define 
the mechanisms of HIV-associated HO-1 protein loss, we examined the regulation of HO-1 by 
immune activators and by soluble factors released by HIV-infected monocyte-derived 
macrophages in rat primary astrocytes. The immune activators TNFα, LPS, and IFNγ modulated 
expression of HO-1, NQO1, and GPX1 proteins in a different manner than previously observed in 
human primary fetal astrocytes, suggesting that immune signaling pathways and/or HO-1 gene 
regulation is different in humans and rats. Finally, we did not observe significant regulation of HO-
1 expression in rat astrocytes exposed to supernatants from HIV-infected monocyte derived 
macrophages, which may be due to differences in species homology of critical receptors and 
signaling pathways or may indicate that soluble factors released by HIV-infected monocyte-
derived macrophages in vitro do not regulate HO-1 expression in astrocytes.  
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3.2 Introduction 
HIV-associated neurocognitive disorders (HAND) are thought to be driven by neuropathological 
processes associated with persistent inflammation and oxidative stress within central and 
peripheral compartments of ART-treated HIV-infected individuals. HIV infection of monocyte-
derived macrophages (MDM)/microglia within the brain promote neuronal injury and associated 
neurocognitive impairment through the release of cytokines, chemokines, and various soluble 
factors that promote neurotoxicity and activation of uninfected cells, including astrocytes. We 
previously identified reduced expression of heme oxygenase-1 (HO-1) protein in HIV-infected 
brain that was relatively selective, as HO-2 and NQO1 were not altered in these brains (170). In 
the preceding chapter, we associated reduced HO-1 protein with increased expression of HO-1 
RNA in HIV-infected brain and our in vitro studies identified IFNγ as an HIV-relevant immune 
activator that drives HO-1 protein infection in human astrocytes through a posttranscriptional 
mechanism. HIV infection of MDM (HIV-MDM) in vitro significantly reduces HO-1 protein and HO-
1 RNA, suggesting a transcriptional mechanism mediates HIV effects in macrophages (106). 
Thus, HIV-infection and associated immune activation is associated with reduction of HO-1 
protein by distinct mechanisms, and in the current work we sought to further define the regulation 
of HO-1 expression in models relevant to HAND. 
 
Classically, HO-1 is induced in response to cytokines, chemokines, and immune stimuli, although 
several studies have reported that HO-1 protein can be reduced by immune signals including 
IFNα, IFNγ, and LPS (171-174). To better understand mechanisms by which immune activators 
may modulate HO-1 expression, we examined the effects of TNFα, LPS, and IFNγ in rat primary 
astrocytes to determine if the IFNγ-driven HO-1 protein loss observed in human astrocytes is 
conserved between species. Within the brain of HIV-infected individuals, reduced expression of 
HO-1 protein was associated with markers of macrophage/microglia activation, suggesting that 
HIV-infected monocyte-derived macrophages (HIV-MDM) may directly modulate HO-1 expression 
(106). Release of factors such as viral proteins, TNFα, arachidonic acid, prostaglandins, reactive 
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oxygen species, and immune activators from HIV-infected MDM/microglia can activate astrocytes 
and impair their glutamate handling functions (175-183). To determine if soluble factors released 
by HIV-MDM alter expression of HO-1, we exposed primary rat astrocytes to supernatants from 
uninfected Mock-MDM and HIV-MDM for 15-days.  
 
3.3 Materials and Methods 
Study approvals 
Primary rat cerebrocortical cultures were prepared in accordance with the NIH Guidelines for the 
Care and Use of Laboratory Animals and protocols were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee (IACUC). All human studies and 
protocols for isolation of monocytes were reviewed and approved by the University of 
Pennsylvania Institutional Review Board (IRB) and all participants provided written informed 
consent. 
Rat primary cerebrocortical astrocyte culture  
Cell suspensions from cortices of embryonic day 17 (E17) Sprague Dawley rat pups were 
prepared by the University of Pennsylvania Mahoney Institute of Neurological Sciences (MINS) 
Neuron Culture Service Center and 15 x 106 cells were plated to a T75 flask coated with poly-D-
lysine (PDL; Sigma-Aldrich). The mixed neuronal/glial cultures were maintained in rat astrocyte 
media (DMEM (Gibco) supplemented with 5% FBS (HyClone) and 100U/mL penicillin / 100µg/mL 
streptomycin (Gibco)) to stimulate astrocyte growth and maintained at 37°C and 5% CO2 for 7 
days. After shaking (260rpm) flasks overnight at 37°C, detached cells were removed by washing 
and the remaining attached cells were replated to a PDL coated T75 flask to obtain purified 
astrocytes. Three days later, astrocyte cultures were plated to tissue culture plates and PDL 
coated glass coverslips as necessary for experiments and maintained an additional 3 days before 
use in experiments. At the start of all treatments, rat astrocyte cultures were switched to MDM 
media (DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone), 10% horse 
serum (Invitrogen), 1% nonessential amino acids (Invitrogen), 2mM L-glutamine (Gibco), and 
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100U/mL penicillin / 100µg/mL streptomycin (Gibco) and cultures were maintained in MDM media 
for the duration of experiments.  
Isolation and culture of human monocyte-derived macrophages (MDM) 
Human monocytes were isolated from healthy donors by Ficoll density gradient centrifugation and 
plated at 1.05 x 105 cells/cm2 in Cell-Bind plates (Corning) as previously described (105). Cells 
were cultured in MDM media (DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS; 
HyClone), 10% horse serum (Invitrogen), 1% nonessential amino acids (Invitrogen), 2mM L-
glutamine (Gibco), and 100U/mL penicillin / 100µg/mL streptomycin (Gibco)) and maintained at 
37°C and 6% CO2. Cells were cultured for 7 days in vitro (DIV) and visually inspected for MDM 
differentiation before use in HIV infection experiments.  
HIV infection of MDM 
Differentiated MDM were inoculated with 50ng (measured by p24 ELISA) of HIV-1 Jago (R5 
strain) or HIV-1 89.6 (R5/X4 strain) per 106 cells for 24 hours and the following day cells were 
washed twice with PBS and incubated with fresh MDM media. HIV-1 Jago is a macrophage tropic 
primary isolate derived from cell-free cerebrospinal fluid (CSF) of a patient with confirmed HIV-
associated dementia (184). HIV-1 89.6 is a molecular clone of a macrophage tropic strain 
originally derived from the peripheral blood of a patient with AIDS but no neurological disease 
(185). Virus stocks were prepared by the University of Pennsylvania Center for AIDS Research 
(CFAR) Virology Core. Supernatants from HIV-infected MDM (HIV-MDM) or uninfected MDM 
(mock-MDM) were collected every 3 days and stored at -80°C. 
HIV reverse transcriptase activity assay 
HIV replication was quantified in supernatants using a viral reverse transcriptase (RT) assay 
measuring incorporation of radiolabeled deoxythymidine. Briefly, 10µL of supernatant was 
incubated overnight at 37°C with 50µL of RT cocktail (50µM Tris pH 7.8, 75µM KCl, 5µM MgCl2, 
0.05% NP-40, 2µM DTT, 5µg/mL 1.6mU poly(rA).p(dT)12-18, and 10µCi/mL dTTP[α-32P] (Perkin 
Elmer)). 30µL of sample was dotted onto DE81 Whatman ion exchange cellular chromatography 
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paper (Fisher Scientific), air dried for 30 minutes, washed four times with 2x UltraPure saline 
sodium citrate (SCC) buffer (300mM NaCl, 30mM sodium citrate, pH 7.0; Invitrogen), washed 
once in absolute ethanol, and dried at 80-100°C for 30 minutes. The samples on Whatman paper 
were then added to scintillation vials with 5mL of Scintiverse BD cocktail (Fisher Scientific) and 
counted for 32P in a liquid scintillation counter (Wallace LKB). 
Exposure of rat astrocytes to immune activators 
Stock solutions of purified lipopolysaccharide (LPS; Sigma-Aldrich), recombinant rat TNFα 
(Peprotech), and recombinant rat IFNγ (Peprotech) were prepared in sterile phosphate buffered 
saline (PBS) and stored at -20°C until use. Cells were treated with LPS (1µg/mL), TNFα 
(10ng/mL), IFNγ (10ng/mL), or vehicle (PBS) alone or in combination for 1 hour, 6 hours, 24 
hours or 15 days and media and treatment was replaced every 3 days.  
Exposure of rat astrocytes to MDM supernatants 
Rat primary astrocytes were exposed to MDM media (UT- untreated) and MDM supernatants 
from uninfected (mock-MDM) and HIV-infected (HIV-MDM) experiments for 15 days. Mock-MDM 
and HIV-MDM supernatants collected on day 12 of infection were diluted 1:3 in MDM media and 
the same supernatant stocks were used throughout each experiment. Every 3 days media and 
MDM supernatant treatments were replaced and aliquots of the astrocyte supernatant and the 
MDM supernatant were saved for analysis of HIV replication by viral RT assay as described 
above.  
Immunofluorescence 
To detect GFAP expression in primary rat astrocyte cultures, cells were plated onto PDL coated 
glass coverslips in 35mm dishes at a density of 1.5 x 105 cells per dish. At indicated time points, 
coverslips were removed and cells were fixed in 4% paraformaldehyde/4% sucrose solution 
(Affymetrix Inc.) for 20 minutes at 4°C and 0.2% Triton-X for 10 minutes at 4°C. Coverslips were 
blocked for one hour in PBS with 10% goat serum and incubated for one hour with primary 
mouse monoclonal antibody against GFAP (0.59µg/mL; Cell Signaling Technology) diluted 1:500 
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in PBS with 10% goat serum. After 6 washes in PBS, coverslips were incubated for one hour with 
goat anti-mouse FITC secondary antibody (10µg/mL; Sigma-Aldrich) and Hoescht 33342 
(1µg/mL; Invitrogen Molecular Probes) in PBS with 10% goat serum and 25% FBS. Coverslips 
were washed 6 times in PBS and mounted on glass slides with Fluoromount-G 
(SouthernBiotech). 
RNA extraction and qPCR 
Cell cultures were rinsed with ice cold PBS and total RNA was prepared using the RNeasy Micro 
Kit (Qiagen). RNA Purity and concentration was measured with NanoDrop 2000c UV-Vis 
spectrophotometer (Thermo Fisher Scientific) and 1µg of total RNA was reverse transcribed to 
single-stranded cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Relative RNA expression was determined by quantitative real-time PCR (qPCR) 
using 50ng cDNA, TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and TaqMan 
primer/probe sets (HMOX1:Hs01110250_m1; GAPDH: Hs01558390_m1; Applied Biosystems) in 
20µL reaction volumes. Reactions were run in technical triplicate on the 7500 Fast Real-Time 
PCR System (Applied Biosystems). GAPDH was used as the reference gene and RNA 
expression was calculated relative to the corresponding vehicle condition using the ΔΔCq 
method. 
Protein extraction and Western blot 
Protein extraction and fluorescent Western blot procedures were performed as described in 
section 2.3. Primary and secondary antibodies used in rat astrocyte experiments are listed in 
Table 3.1. Membranes were scanned with the Odyssey CLx Infrared Imaging System (LI-COR 
Biosciences) and background-corrected signal intensity of protein bands was determined using 
Image Studio Lite software (LI-COR Biosciences). Protein expression was normalized to β-tubulin 
and fold change was calculated relative to the vehicle condition. 
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Statistics 
All quantifications are expressed as mean ± standard error mean (SEM) and protein and RNA 
expression data were log transformed. Statistical comparisons of three or more groups were 
made by repeated measures one-way ANOVA with Holm-Sidak post-test. All statistical analyses 
were performed using GraphPad Prism 7 software (GraphPad Software). Significance was 
defined as *P <0.05, **P <0.01, ***P <0.001. 
 
3.4 Results 
Rat primary astrocyte cultures maintain their cellular phenotype throughout 29-days of culture 
With the goal of developing an in vitro model useful for studying effects of soluble factors 
released by HIV-infected macrophages (HIV-MDM) on astrocyte function, we assessed the purity 
of rat primary astrocyte cultures maintained up to 29 days in vitro (DIV). Primary astrocyte 
cultures derived from cortices of embryonic rat pups (E17) are highly enriched for astrocytes at 
DIV 14, however we proposed to expose these well characterized DIV 14 cultures to 
supernatants from HIV-MDM for an additional 15 days in order to model chronic processes 
associated with CNS HIV infection. These experiments would also necessitate culturing the 
primary astrocytes in MDM medium, which has a significantly higher total serum content (20%) 
compared to the standard astrocyte culture media (5% serum). We therefore examined 
expression of glial fibrillary acid protein (GFAP), an astrocyte specific cytoskeletal protein, in cells 
cultured in MDM media beginning on DIV 14 and further maintained in MDM media up to DIV 29. 
As depicted in Figure 3.1A, nearly all cells in the DIV 14 cultures (replated at low density on DIV 
11) express GFAP protein. Over the next 15 days, the cultures show significant proliferation and 
GFAP staining remains robust 3, 9, and 15 days after changing the culture conditions to MDM 
medium (Figure 3.1B-D). These data indicate that rat astrocytes maintain their cellular phenotype 
when cultured for 15 days in medium with high serum content and suggested that these rat 
primary astrocyte cultures would be an appropriate model for studying the regulation of HO-1 
expression and glutamate functions in astrocytes. 
63  
Soluble factors released by HIV-MDM do not modulate HO-1, NQO1, or GPX1 protein expression 
in rat astrocytes. 
To examine if soluble factors released by HIV-MDM regulate HO-1 expression in astrocytes, we 
exposed rat primary astrocytes to supernatants (diluted 1:3 in media) from mock-MDM and HIV-
MDM for 15 days. The supernatants/media were replaced every 3 days and HIV activity was 
measured in aliquots of the MDM supernatant added to cells and in the astrocyte supernatant 
collected from cells. As expected, no viral activity was observed in Mock-MDM supernatants, or in 
astrocyte supernatants collected from cells exposed to Mock-MDM or left untreated (Fig. 3.2A). 
The HIV-MDM supernatants added to astrocytes showed high RT activity indicating that these 
supernatants were indeed from MDM infected with HIV. Astrocyte supernatants collected 3-days 
after the HIV-MDM was added showed RT activity that was always lower than the activity 
measured in the HIV-MDM supernatant added, confirming that productive infection was not 
established in the primary rat astrocyte cultures and that the virus in the HIV-MDM supernatants 
was not significantly imported into or destroyed by the astrocytes. After 15-days of exposure, 
there was no change in HO-1, NQO1, and GPX1 protein expression (Fig. 3.2B, 3.2C).  
One-hour exposure of rat astrocytes to TNFα induces HO-1 and NQO1 proteins 
One-hour exposure to the panel of immune activators did not significantly alter HO-1 RNA (Fig. 
3.3A). TNFα significantly induced HO-1 and NQO1 protein after one hour of exposure, but did not 
alter GPX1 protein (Fig. 3.3B, 3.3C, 3.3D, 3.3E).  
Six-hour exposure of rat astrocytes to HIV-associated immune activators reduces HO-1 protein 
HO-1 RNA expression remained unchanged after 6-hour exposure to the immune activators (Fig. 
3.4A), but HO-1 protein was significantly reduced by all treatments except IFNγ, which resulted in 
a small but statistically significant increase in HO-1 protein (Fig. 3.4B, 3.4C). NQO1 protein was 
not significantly changed by any condition, suggesting that the increase observed after one hour 
exposure to TNFα is not sustained (Fig. 3.4D). Similar to effects observed at one hour, GPX1 
protein was not changed after 6 hour exposure (Fig. 3.4E) 
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One-day exposure of rat astrocytes to LPS induces NQO1 and GPX1 proteins  
After 24 hours, no changes in HO-1 RNA (Fig. 3.5A) or protein (Fig. 3.5B, 3.5C) were evident. 
LPS significantly induced NQO1 and GPX1 proteins at 24 hours, and LPS + IFNγ resulted in 
significantly reduced NQO1 (Fig. 3.5D, 3.5E). 
15- day exposure of rat astrocytes to LPS+IFNγ reduces HO-1 and GPX1 proteins 
After prolonged, 15-day exposure, no changes in HO-1 RNA were evident (Fig. 3.6A). Protein 
expression of HO-2, HO-1, NQO1, and GPX1 was not altered by TNFα, LPS, IFNγ, TNF + LPS, 
or TNFα + IFNγ (Figure 3.6B-F). However, exposure to LPS + IFNγ significantly reduced HO-1 
and GPX1 protein expression (Fig. 3.6D, 3.6F).  
 
3.5 Discussion 
Exposure of rat primary astrocytes to HIV-MDM supernatants for 15 days did not modulate 
expression of HO-1, NQO1, or GPX1, despite the presence of HIV virions in the HIV-MDM 
supernatants. This suggests that viral proteins do not alter HO-1 expression in rat astrocytes, but 
an effect of viral particles cannot be completely ruled out until similar experiments are performed 
using human astrocytes. Similarly, immune activators including cytokines and chemokines that 
are present in HIV-MDM supernatants may have failed to exert effects on HO-1 due to intrinsic 
species differences in homology between rat and human immune signaling receptors. Soluble 
factors in the supernatants that are not likely to depend on species-specific expression of 
receptors and other signaling molecules, including glutamate and reactive oxygen species, were 
likely active on rat astrocytes, but the current data suggest that they do not regulate HO-1 
expression in rat astrocytes. Repeating these experiments using human primary astrocytes will 
be more informative, since species-specific differences in cytokine and chemokine receptors and 
signaling pathways will not influence the observed effects on HO-1.  
 
TNFα, LPS, and IFNγ did not produce consistent changes in expression of HO-1, NQO1, or 
GPX1 that were maintained across time. Prolonged exposure to LPS in combination with IFNγ 
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reduced HO-1 and GPX1 proteins, though neither treatment alone produced an effect. This 
suggests that HO-1 can be regulated by immune activation, but may require action of multiple 
factors working together to drive reduced HO-1 protein. Additionally, the posttranscriptional 
regulation of HO-1 by IFNγ that we observed in human primary astrocytes was not recapitulated 
in rat astrocytes. Regulation of HO-1 by immune activators thus appears to occur via different 
mechanisms in rat and human astrocytes. Species-specific differences could result from 
alternative downstream signaling pathways utilized by rat and human immune activators or 
available to immune activators in rat and human astrocytes, or could be due to species 
dependent differences in the HO-1 genome. For example, rat HO-1 gene expression is regulated 
by members of the heat-shock factor (HSF) family by binding to heat shock element (HSE) 
consensus regions within the promoter, but human and mouse HO-1 is not regulated by HSF, 
and this seems to be due to mutations within the HSE loci that render them inactive (150). In 
sum, these data highlight the potential difficulties associated with comparing effects across 
different cell types and/or species and underscore the importance of critically assessing the 
usefulness and relevance of new models.  
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Table 3.1 Primary and secondary antibodies used for Western blotting in primary rat 
astrocytes. 
Abbreviations: monoclonal antibody (mAb); polyclonal antibody (pAb). 
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3.6 Figures 
 
Figure 3.1 Expression of GFAP is maintained over time in rat primary astrocyte cultures. 
Rat primary astrocyte cultures prepared from E17 cortices were plated to PDL coated glass 
coverslips on DIV 11 and cultured in MDM media starting on DIV 14. Cells were fixed at (A) DIV 
14, (B) DIV 17, (C) DIV 23 and (D) DIV 29, corresponding to days 0, 3, 9, and 15 of experimental 
treatment paradigms. Immunofluorescence was used to assess expression of the astrocyte 
specific marker GFAP in cells identified using the nuclear stain Hoescht 33342. Scale bar = 
100µm. 
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Figure 3.2 HIV-infected macrophage supernatants do not alter protein expression of ARE-
driven genes in rat primary astrocytes. 
Rat primary rat astrocytes were cultured in macrophage media (untreated) or exposed to mock-
infected (Mock-MDM) and HIV-infected (HIV-MDM) macrophage supernatants for 15 days and 
medium and supernatants were replaced every 3 days. (A) HIV replication was measured by RT 
assay in rat astrocyte supernatants collected every third day following replacement medium and 
supernatants. HIV replication was also determined for each MDM supernatant/medium dilution 
applied to astrocyte cells. Data represent mean ± SEM (n= 2 biological replicates). (B) Western 
blot of n=2 independent rat astrocyte cultures. (C) HO-1, NQO1 and GPX1 protein expression in 
rat astrocytes was quantified relative to untreated after normalization to βtubulin. The mean 
vehicle expression was set to 1 (dotted line). Bars represent mean ± SEM (n= 2 biological 
replicates).  
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Figure 3.3 HO-1 and NQO1 proteins are induced after one-hour exposure to TNFα in rat 
astrocytes. 
Rat primary astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ (10ng/mL) 
alone or in combination for 1 hour and RNA and protein expression was measured by qPCR and 
Western blot. (A) HO-1 RNA expression was quantified relative to vehicle after normalization to 
GAPDH. (B) Representative Western blot from a single biological replicate. (C) HO-1, (D) NQO1, 
and (E) GPX1 protein expression was quantified relative to vehicle after normalization to βtubulin. 
The mean vehicle expression was set to 1 (dotted line). Bars represent mean ± SEM (n= 4 
biological replicates). Statistical comparisons to vehicle were made by repeated measures 
ANOVA (RM-ANOVA) with post hoc Holm-Sidak test. *P < 0.05, **P < 0.01 
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Figure 3.4 HO-1 protein is decreased after 6-hour exposure to HIV-associated immune 
activators in rat astrocytes. 
Rat primary astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ (10ng/mL) 
alone or in combination for 6 hours and RNA and protein expression was measured by qPCR and 
Western blot. (A) HO-1 RNA expression was quantified relative to vehicle after normalization to 
GAPDH. (B) Representative Western blot from a single biological replicate. (C) HO-1, (D) NQO1, 
and (E) GPX1 protein expression was quantified relative to vehicle after normalization to βtubulin. 
The mean vehicle expression was set to 1 (dotted line). Bars represent mean ± SEM (n= 4 
biological replicates). Statistical comparisons to vehicle were made by repeated measures 
ANOVA (RM-ANOVA) with post hoc Holm-Sidak test. *P < 0.05, **P < 0.01. 
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Figure 3.5 NQO1 and GPX1 proteins are induced after 24-hour exposure to LPS in rat 
astrocytes. 
Rat primary astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ (10ng/mL) 
alone or in combination for 24 hours and RNA and protein expression was measured by qPCR 
and Western blot. (A) HO-1 RNA expression was quantified relative to vehicle after normalization 
to GAPDH. (B) Representative Western blot from a single biological replicate. (C) HO-1, (D) 
NQO1, and (E) GPX1 protein expression was quantified relative to vehicle after normalization to 
βtubulin. The mean vehicle expression was set to 1 (dotted line). Bars represent mean ± SEM (n= 
3-4 biological replicates). Statistical comparisons to vehicle were made by repeated measures 
ANOVA (RM-ANOVA) with post hoc Holm-Sidak test. *P < 0.05, ***P < 0.001 
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Figure 3.6 HO-1 and GPX1 proteins are reduced after 15-day exposure to LPS + IFNγ in rat 
astrocytes. 
Rat primary astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ (10ng/mL) 
alone or in combination for 15 days and medium and treatments were replaced every 3 days. 
RNA and protein expression was measured by qPCR and Western blot. (A) HO-1 RNA 
expression was quantified relative to vehicle after normalization to GAPDH. (B) Representative 
Western blot from a single biological replicate. (C) HO-2, (D) HO-1, (E) NQO1, and (F) GPX1 
protein expression was quantified relative to vehicle after normalization to βtubulin. The mean 
vehicle expression was set to 1 (dotted line). Bars represent mean ± SEM (n= 5-6 biological 
replicates). Statistical comparisons to vehicle were made by repeated measures ANOVA (RM-
ANOVA) with post hoc Holm-Sidak test. **P < 0.01 
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4.1 Abstract 
The continued prevalence of HIV-associated neurocognitive disorders (HAND) indicates that 
antiretroviral therapy (ART) is incompletely effective at suppressing mechanisms responsible for 
neuronal injury and damage associated with HIV infection including chronic immune activation 
and oxidative stress. We previously linked reduced expression of heme oxygenase-1 (HO-1) 
protein to HAND and demonstrated a functional role for HO-1 in modulating extracellular 
glutamate in HIV-infected macrophages. Within the brain, astrocytes are critical regulators of 
glutamate handling and dysregulation of glutamate functions within this important cell type is 
likely to contribute to neuronal dysfunction in HIV-infected individuals. To determine if HO-1 
dysregulates glutamate handling within astrocytes, we used pharmacological and genetic 
approaches to manipulate HO-1 expression in human and rat primary astrocytes. Additionally, we 
assessed the role of immune activation on astrocyte glutamate function by treating cells with the 
HIV-relevant immune activators TNFα, LPS, and IFNγ. Modulation of HO-1 expression by siRNA 
knockdown or pharmacologic inhibition of enzymatic activity did not alter glutamate uptake, 
extracellular concentrations of glutamate, or flux of amino acids to intracellular and extracellular 
compartments. Exposure of primary human astrocytes to TNFα for 24 hours and 15 days 
significantly increased extracellular glutamate, while 15 day exposure to IFNγ significantly 
reduced extracellular glutamate. The results of these experiments suggest that glutamate 
handling functions within astrocytes of HIV-infected individuals may be regulated by the 
interactions of multiple cellular factors and mechanisms, including IFNγ-driven mechanism . 
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4.2 Introduction 
Although the incidence of HIV-associated dementia (HAD) and HIV encephalitis (HIVE), the most 
severe forms of HIV neurological disease, has decreased since the introduction of effective 
antiretroviral treatment (ART), milder forms of HIV-associated neurocognitive disorders (HAND) 
persist in a significant proportion (30-50%) of ART-treated patients and are associated with loss 
of synaptic density, dendritic simplification, white matter volume loss, and altered neuronal 
metabolism (38-40, 145, 147, 148, 186, 187). Neuronal dysfunction in HAND is likely mediated by 
HIV-infected macrophages (HIV-MDM) and immune activated MDM, microglia, and astrocytes 
through release of soluble factors, including the excitatory neurotransmitter glutamate. Glutamate 
levels are elevated in the cerebrospinal fluid (CSF) of HIV-infected individuals compared to non-
infected individuals and further were shown to correlate with severity of brain atrophy and 
dementia (188). CSF glutamate likely reflects extracellular glutamate, which at high levels can 
cause N-methyl-D-Aspartate Receptor (NMDAR) mediated excitotoxicity and neuronal death. 
Post-mortem ligand binding studies revealed significant reduction of NDMAR density and 
glutamate uptake sites within the frontal cortex of individuals with AIDS and HIV-associated 
dementia (HAD) compared to non-infected individuals, which is suggestive of neuronal loss due 
to NMDAR-mediated neurotoxicity (189). Multiple studies have demonstrated that in vitro, 
extracellular glutamate is increased in supernatants from HIV-MDM and that neurotoxicity of HIV-
MDM supernatants is largely dependent on elevated glutamate (190-194).  
 
The mechanism(s) responsible for increased extracellular glutamate observed in HIV-MDM and 
the CNS of HIV-infected individuals is incompletely explained, but could arise from increased 
release, decreased uptake, and/or dysregulation of glutamate metabolism. Within the brain, 
astrocytes are crucial for maintenance of glutamate homeostasis and are responsible for uptake 
of ~80% of glutamate in the extracellular space (195). Astrocytes have abundant expression of 
high affinity sodium (Na+) dependent excitatory amino acid transporters (EAATs) that are 
responsible for the majority of glutamate uptake, but are also capable of transporting glutamate 
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through Na+ independent mechanisms including vesicular glutamate transporters (VGLUTs) and 
rarely through the cystine-glutamate antiporter (xCT) (195, 196). Intracellular glutamate in 
astrocytes can be converted to glutamine, glutathione, or oxidized to α-ketoglutarate which can 
be further metabolized through the tricarboxylic acid cycle (TCA). The metabolic fate of glial 
glutamate is dependent on extracellular concentrations of glutamate, activity of metabolic 
enzymes, availability of amino acids, and energy needs of the cell (195-197). Non-vesicular 
release of glutamate by astrocytes occurs through the xCT antiporter which typically mediates the 
stoichiometric exchange of extracellular cystine for intracellular glutamate, but the direction of this 
exchange can be reversed under conditions of high extracellular glutamate (198).  
 
HIV-driven dysregulation of glutamate homeostasis within astrocytes may potentially occur via 
direct effects of viral proteins or through indirect effects of HIV-associated immune activators. The 
viral protein gp120 has been shown to decrease expression of EAAT glutamate transporters and 
to inhibit glutamate uptake in human astrocytes (199-201). Additionally, TNFα and LPS inhibit 
activity of the EAAT1 promoter, reduce expression of EAAT1 and EAAT2 mRNA and/or protein, 
and reduce glutamate uptake in astrocytes (179, 199, 202-204). Within the brain of HIV-infected 
individuals, direct and indirect effects of HIV in concert may further enhance the dysregulation of 
glutamate, as suggested by the finding that HIV-MDM glutamate mediated neurotoxicity is 
enhanced by activation of MDM with LPS (190). As we previously established that HO-1 protein 
loss is a conserved phenotype of chronically infected HIV-MDM that consistently associates with 
elevated extracellular glutamate and furthermore demonstrated that induction of HO-1 expression 
in HIV-MDM attenuates extracellular glutamate, we hypothesized that HO-1 may similarly 
modulate glutamate homeostasis in astrocytes (106, 170). In the current work, we examined 
glutamate uptake, extracellular glutamate, and glutamate metabolism in astrocytes after exposure 
to the HIV-relevant immune activators TNFα, LPS, and IFNγ and after genetic or pharmacological 
manipulation of HO-1 expression. Although we did not identify a functional role for HO-1 in 
glutamate handling in astrocytes, these preliminary experiments provide an important framework 
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for additional experiments addressing the role HO-1 and immune activation on modulating 
glutamate homeostasis within astrocytes. 
 
4.3 Materials and Methods 
Study approvals 
Human primary fetal astrocyte cultures were prepared from fetal brain tissue obtained from 
elective abortion procedures performed in full compliance with National Institutes of Health and 
Temple University ethical guidelines and approved by the IRB of Temple University. Rat primary 
cerebrocortical cultures were prepared in accordance with the NIH Guidelines for the Care and 
Use of Laboratory Animals and protocols were approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee (IACUC). 
HEK293 cell culture 
Human Embryonic Kidney 293 cells (HEK293) were cultured in Minimum Essential Media (MEM; 
Gibco) supplemented with 5% FBS, 5% horse serum, 2mM L-glutamine, 100U/mL penicillin, and 
100µg/mL streptomycin (Gibco) and maintained at 37°C and 5% CO2. for at least 24 hours before 
initiating treatment 
Culture and treatment of human primary fetal astrocytes  
Human primary human fetal astrocyte cultures were generously provided by the Basic Science 
Core I of the Comprehensive NeuroAIDS Center (CNAC) at Temple University School of 
Medicine and prepared as described in section 2.3. Stock solutions of purified lipopolysaccharide 
(LPS; Sigma-Aldrich), recombinant human TNFα (Peprotech), and recombinant human IFNγ 
(Peprotech) were prepared in sterile phosphate buffered saline (PBS). Cells were exposed to 
PBS vehicle, LPS (1µg/mL), TNFα (10ng/mL), and IFNγ (10ng/mL) alone or in combination for 24 
hours or 15 days. Medium and treatment were replaced every 3 days.  
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siRNA knockdown  
Human primary human fetal astrocytes were transfected with 10nM Silencer Select siRNAs 
(Ambion) using Lipofectamine RNAiMax (Invitrogen). Lipofectamine reagent and siRNA were pre-
incubated for 10 minutes in Opti-MEM (Invitrogen) prior to addition to cells. Control conditions 
included addition of lipofectamine reagent alone and transfection with siRNA against scramble 
target (#4390846). siRNA targeting HO-1 (s6673) or HO-2 (s6675) was used to knockdown HO-1 
and HO-2 proteins, respectively. siRNA targeting BACH1 (s1859), a negative transcriptional 
regulator of HO-1, was used knockdown BACH1 protein and indirectly induce HO-1 expression. 
siRNAs targeting HO-1 and BACH1 were applied in combination to assess HO-1 specific 
contributions to BACH1 effects. All knockdown experiments were confirmed using Western blot 
techniques as described in section 2.3.  
Culture and treatment of rat primary astrocytes 
Cell suspensions from E17 rat cortices were provided by the University of Pennsylvania Mahoney 
Institute of Neurological Sciences (MINS) Neuron Culture Service Center and rat primary 
astrocyte cultures were prepared and maintained as described in section 3.3. Stock solutions of 
Sn(IV) Mesoporphyrin IX dichloride (SnMP; Frontier Scientific) were prepared in sterile 1N NaOH, 
stored at -20°C until use, and applied at concentration of 20µM. SnMP inhibits enzymatic activity 
of HO-1 and HO-2 and activity was confirmed by measuring the induction of HO-1 protein 
(resulting from inhibition of HO-1 activity) by Western blot techniques described in section 3.3.  
[3H] glutamate uptake assay 
Cells plated to 48 well plates were pre-incubated in 250µL HBSS (8.4mM HEPES, 3mM KCl, 
143mM NaCl/ChCl, pH 7.3) supplemented with 2.5% FBS for 1 hour at 37°C, solution was 
removed, and 250uL HBSS containing 34nM [3, 4-3H] L-glutamatic acid (51.1 Ci/mmol, Perkin 
Elmer) was added and cells were further incubated at 37°C. At indicated times, incubation 
solution was removed, cells were washed in ice cold PBS, and lysed in 300µL of 0.2N NaOH 
containing 0.5% Triton-X 100. Lysates (250µL) were added to scintillation vials containing 5mL of 
Scintiverse BD cocktail (Fisher) and 3H was measured in a liquid scintillation counter (Wallace 
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LKB). Na+ dependent and Na+ independent uptake was assessed by incubation in HBSS 
containing 143mM NaCl or 143mM ChCl. All experiments were performed in technical triplicate. 
In experiments comparing primary human fetal astrocytes and HEK cells, [3H] glutamate was 
assessed on DIV 4. In experiments assessing effects of siRNA knockdown, cells were transfected 
with siRNA on DIV 1 and uptake after 15 minute incubation with [3H] glutamate was measured on 
DIV 4 (Day 3 of siRNA) and DIV 7 (Day 6 of siRNA). 
Extracellular glutamate assay 
Extracellular glutamate concentration was measured in supernatants assayed in technical 
triplicate using the Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen) 
according to the manufacturer’s instructions. In an attempt to remove possible interfering 
substances from supernatants, samples were deproteinized by addition of 1 volume of 4% 
perchloric acid (PCA) and spun down at 10,000 rpm for 5 minutes to pellet insoluble material. The 
resulting supernatant was neutralized (pH 7-8) by addition of KOH and spun down at 6,000 rpm 
for 10 minutes to remove salts.  
HPLC measurement of intracellular and extracellular amino acids in rat astrocytes 
Rat primary astrocytes were plated to 10cm dishes for High Performance Liquid Chromatography 
(HPLC) analyses and in parallel, plated to 6 well plates for Western blot analyses on DIV 11. 
Astrocyte media was removed and replaced with MDM media on DIV 14 and cells were 
maintained in MDM media for the duration of experiments. On DIV 18, media was refreshed and 
cells were treated with NaOH or 20µM SnMP for 72 hours. On DIV 21, media and treatment were 
refreshed and for 0h time point, supernatants and cells were immediately collected. After an 
additional 24 hours, supernatants and cells were again collected. For analysis of intracellular 
amino acids, cells were washed in ice cold PBS, scraped in ice cold 4% PCA containing amino 
acid standards, subjected to 3 freeze thaw cycles at -80°C, and spun down at room temperate for 
5 minutes at 2500 rpm and the protein pellet was saved for assay of protein concentration. The 
supernatant was neutralized (pH 7-8) by addition of KOH and samples were spun down at 2500 
rpm for 5 minutes to remove salts. The resulting supernatant was analyzed by HPLC. The protein 
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pellet was resuspended in 1N NaOH, incubated at 37°C until completely dissolved, and protein 
concentration was measured using the Detergent Compatible (DC) protein assay (Bio-Rad). 
HPLC and data analysis was performed by the Metabolomics Core of the Children’s Hospital of 
Philadelphia.  
 
4.4 Results 
siRNA-mediated knockdown of HO-1 does not alter glutamate uptake of human primary 
astrocytes 
Given that altered glutamate handling functions in astrocytes, including reduced uptake of 
extracellular glutamate, have been suggested to contribute to HAND and our previous work has 
established a role for HO-1 in the modulation of MDM glutamate handling, we investigated 
whether loss of HO-1 alters glutamate uptake through sodium (Na+) dependent and Na+ 
independent transporters in human primary fetal astrocytes (106, 170). Human astrocytes and 
HEK293 cells exhibited linear uptake of glutamate over 45 minutes under conditions with and 
without Na+ (Fig 4.1A). Total glutamate uptake and Na+ dependent uptake was more robust in 
human astrocytes as compared to HEK293 cells, but Na+ independent uptake was similar 
between these two cell types (Fig. 4.1B). To test the contribution of HO-1 to astrocyte glutamate 
uptake, we utilized siRNA to knockdown HO-1 expression and confirmed that 3 days and 6 days 
after single application of HO-1 siRNA, HO-1 protein was expression was dramatically reduced 
(Fig. 4.1C). Glutamate uptake by Na+ dependent and Na+ independent transporters was not 
affected by HO-1 knockdown, but independent of siRNA conditions, Na+ dependent uptake was 
enhanced at day 6 as compared to day 3 (Figure 4.1D). 
siRNA-mediated induction and suppression of HO-1 does not alter extracellular glutamate in 
human astrocytes  
We next examined effects of HO-1 modulation on extracellular glutamate concentrations in 
human primary fetal astrocytes, as altered levels of extracellular glutamate may reflect 
dysregulation of several mechanism of glutamate handling including glutamate uptake, release, 
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and metabolism. To induce HO-1 expression, we used siRNA targeting BTB and CNC homology 
1 (BACH1), a transcription factor that negatively regulates HO-1 expression. Since knockdown of 
BACH1 would be expected to modulate expression of several genes besides HO-1, we used a 
double knockdown approach with both BACH1 and HO-1 siRNA to asses HO-1 specific effects of 
BACH1 knockdown. After 3 days, siRNA against HO-1 dramatically reduced expression of HO-1 
protein without altering expression of HO-2 protein (Fig. 4.2A). Knockdown of HO-2 was also 
effective, but to a lesser extent than that observed for HO-1, possibly due to the longer half-life of 
HO-2 protein as compared to HO-1 (Fig. 4.2A). As expected, BACH1 knockdown induced 
expression of HO-1 protein,and when HO-1 siRNA was added in combination with BACH1 
siRNA, the induction of HO-1 protein was attenuated (Fig. 4.2A). Concentration of extracellular 
glutamate, as measured in cell supernatants with the Amplex Red Glutamic Acid assay kit, was 
not altered by knockdown of HO-1, HO-2, BACH1, or HO-1 + BACH1 (Fig. 4.2B). Although these 
experiments were performed in only one biological experiment and thus no firm conclusions can 
be drawn, induction of HO-1 protein by siRNA-mediated knockdown of BACH1 was associated 
with modest reduction in extracellular glutamate as compared to reduction of protein by siRNA-
mediated knockdown. Repeating these experiments in additional replicates will be important to 
determine if there is a small, but significant, difference between these two conditions.  
TNFα increases extracellular glutamate after 24-hour and 15-day exposure in human astrocytes  
Given that numerous immune activators have been reported to alter glutamate handling in 
astrocytes, we next determined examined extracellular glutamate levels in human primary fetal 
astrocytes exposed to the HIV-relevant immune activators TNFα, LPS, and IFNγ that we 
examined in Chapter 2. After 24 hours, exposure to each of these factors alone and in 
combination significantly reduced extracellular glutamate as compared to the vehicle condition 
(Fig. 4.3A). However, when compared to untreated cells (which were cultured and maintained in 
parallel) glutamate was significantly reduced only in the LPS + IFNγ condition and exposure to 
TNFα resulted in increased extracellular glutamate. After 15-day exposure, supernatant 
glutamate was significantly reduced compared to vehicle in each treatment condition, except 
TNFα alone (Fig. 4.3B). Similar to 24 hours, these effects were different when supernatants from 
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the immune activator conditions were compared with supernatants from untreated cells, as 
glutamate was significantly in supernatants from cells exposed to TNFα alone and significantly 
lower in supernatants from cells exposed to IFNγ alone (Fig. 4.3B). Significantly increased 
extracellular glutamate in vehicle conditions as compared to untreated conditions is an 
unexpected finding, given that the only difference between these conditions is the addition of 
sterile PBS, and led us to speculate that components present within the culture media, such as 
phenol red, may potentially interfere with the Amplex red assay. Alternatively, activation of xCt in 
vehicle conditions could increase the transport of glutamate out of the cell and increase 
extracellular glutamate.  
Inhibition of HO enzymatic activity does not alter clearance of extracellular glutamate or amino 
acid metabolism in rat astrocytes 
As an alternative approach to assess glutamate handling, we next monitored intracellular and 
extracellular flux of amino acids in rat astrocyte cultures by HPLC measurement of amino acid 
concentrations in supernatant and cell lysates collected immediately after replacement of media 
(0h) or 24 hours later. To suppress HO-1 activity, we pre-treated cells for 72 hours with SnMP, a 
potent inhibitor of HO-1 and HO-2 enzymatic activity (205). Since SnMP also induces HO-1 
expression though derepression of the HO-1 promoter, we examined HO-1 expression in cell 
lysates and observed significant induction of HO-1 at the time points assessed in the HPLC 
analyses, suggesting that SnMP was active and likely inhibited HO-1 enzymatic activity in these 
cultures (Fig. 4.4A). The HPLC analyses did not identify effects of HO-1 inhibition on amino acid 
concentrations inside or outside the cell (Fig. 4.4B). In both SnMP and vehicle conditions, 
extracellular glutamate measured at 0h was approximately 80µM and after 24 hours the 
extracellular glutamate had fallen to approximately 10µM. Intracellular glutamate concentrations 
were relatively stable over the same time period, suggesting that glutamate taken up by the 
astrocytes was metabolized.  
 
The concentrations of extracellular glutamate measured by HPLC is in stark contrast to results 
obtained using the Amplex Red kit in the same supernatant samples (Fig. 4.5). Glutamate was 
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measured at ~220µM at 0h and <1µM at 24h, which is significantly different from the 80µM and 
10µM concentrations measured by HPLC. The Amplex Red kit measures generation of a 
fluorescent product dependent on availability of glutamate substrate in the sample and thus 
indirectly measures glutamate concentrations. To determine if substances present in the media, 
such as phenol red and serum enzymes, interfere with the enzymatic activity of this kit we 
deproteinized the same supernatants previously analyzed. After removal of proteins from the 
supernatants, glutamate concentrations measured by the Amplex Red kit at 0h (~60µM) were 
more similar to results obtained with HPLC, but measurements in 24 hour supernatants were still 
lower (~2µM) than values obtained by HPLC (Fig. 4.5).  
 
4.5 Discussion 
The continued prevalence of HAND in ART-treated HIV-infected individuals highlights a critical 
need for novel neuroprotective strategies targeting neuropathological mechanisms that persist 
despite suppression of viral replication. As we previously identified HO-1 as a critical mediator of 
extracellular glutamate and neurotoxicity in HIV-MDM, we hypothesized that HO-1 may similarly 
modulate glutamate handling functions within astrocytes, which are the main regulator of 
glutamate homeostasis in the brain (106). Using genetic and pharmacological approaches to 
reduce HO-1, we did not observe effects of HO-1 loss on extracellular glutamate uptake (Fig. 
4.1), extracellular glutamate concentration (Fig. 4.2), or flux of amino acids through intracellular 
and extracellular compartments (Fig. 4.4). However, lack of observed effects may be due to 
inadequate sample size and these experiments should be repeated in additional replicates.  
 
In human primary fetal astrocytes, 24-hour and 15-day exposure to TNFα significantly increased 
extracellular glutamate as compared to untreated controls, in line with previous reports of TNFα 
mediated inhibition of glutamate uptake in astrocytes (179, 204, 206-208). In contrast, 15-day 
exposure to IFNγ significantly decreased extracellular glutamate as compared to untreated 
controls, suggesting that prolonged exposure to IFNγ enhanced extracellular clearance or 
metabolism of glutamate despite being associated with deficient expression of HO-1 protein. IFNγ 
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was previously shown to enhance clearance of glutamate and increase release of neuroprotective 
thiols and lactate in oxidatively stressed astrocytes, but this was protective role of IFNγ was 
blocked when IL-4 was co-administered, although IL-4 alone had no effects (209) Thus, the 
effects of immune activators and HO-1 on glutamate function within astrocytes are likely to be 
complex and dependent on interactions among multiple factors. 
 
Additionally, we identified a potential technical confound to measuring extracellular glutamate with 
the Amplex Red Glutamic Acid kit. Within the same supernatant samples, glutamate 
concentrations were dramatically different when measured by HPLC compared to the Amplex 
Red kit. Deproteinization of supernatants improved the accuracy of measurements made by the 
Amplex Red kit, but still showed significant variation from HPLC measurements. This kit has been 
used by our lab with consistent and reliable results in supernatants from macrophages, which are 
typically dilutes 20-40x in order to be within the linear range of detection. However, extracellular 
glutamate in astrocyte supernatants appears to much lower compared to macrophage 
supernatants, likely due to the enhanced glutamate clearance functions of astrocytes. This 
prohibits extensive dilution of supernatants for use with the Amplex Red kit and potentially leads 
to higher levels of media components, such as phenol red or serum enzymes, that may 
significantly interfere with the enzymatic reaction producing a fluorescent product that is 
quantified as an indirect measure of glutamate. These data suggest that this indirect method 
lacks the sensitivity and at times the specificity necessary to accurately detect glutamate.  
 
Importantly, we were able to validate several experimental approaches that will be useful for 
future investigation of glutamate handling in astrocytes. Human primary fetal astrocyte cultures 
exhibited greater uptake of 3H glutamate than the HEK239 cell line and furthermore the bulk of 
glutamate uptake in astrocytes was through Na+ dependent mechanisms, confirming that human 
primary fetal astrocyte behave similarly to in vivo astrocytes and are a useful model to study 
astrocyte function in vitro. The siRNA approaches we employed in human primary fetal astrocytes 
were very effective in reducing HO-1 expression, with a single siRNA transfection sufficient to 
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sustain HO-1 reduction for up to 6 days. As neurocognitive dysfunction in HIV-infected individuals 
develops over a period of years and in vitro IFNγ-mediated HO-1 protein loss in human 
astrocytes requires prolonged (15-day) exposure, establishment of models with persistent 
dysregulation of HO-1 will be crucial for further dissection of neuropathogenic mechanisms 
relevant to HAND.  
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4.6 Figures 
 
Figure 4.1 Human primary fetal astrocytes display robust glutamate uptake that is not 
altered by siRNA mediated knockdown of HO-1 expression. 
Glutamate uptake in human primary fetal astrocyte (HFA) and HEK293 (HEK) cells was assessed 
by measuring intracellular radioactivity after incubation with 34nM [3H]-glutamate indicated time 
points. Sodium (Na+) dependent and independent transport mechanisms were assessed by 
conducting assays in the presence of 143mM NaCl or 143mM ChCl, respectively. (A-B) HFA and 
HEK cells (in technical triplicate) were lysed at indicated time points after addition of [3H]-
glutamate and radioactivity was quantified by [3H] liquid scintillation counting (A) Data represent 
mean CPM ± SEM of 3 technical replicates from one experiment. (B) Data represent mean CPM 
of the same 3 technical replicates shown in (A). (C-D) Human primary fetal astrocytes were 
transfected with control siRNA (scr) or siRNA targeting HO-1 (HO-1) using Lipofectamine 
RNAiMax or treated with Lipofectamine RNAiMAX alone (UT) and media was replaced after 3 
days. (C) Western blot of cell lysates collected 3 days and 6 days after transfection. (D) 
Glutamate uptake assays were performed in cells after 3 and 6 days exposure to siRNA. Cells 
were lysed 15 minutes after addition of [3H]-glutamate radioactivity was quantified by [3H] liquid 
scintillation counting. Bars represent mean CPM from n=3 technical replicates. Na+ dependent 
glutamate uptake was calculated by subtracting Na+ independent uptake (measured in the 
presence of ChCl) from total uptake (measured in the presence of NaCl).  
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Figure 4.2 Knockdown of HO-1, HO-2, and BACH1 by siRNA does not modulate 
extracellular glutamate in human astrocytes. 
Human primary fetal astrocytes were transfected with using scramble negative control siRNA 
(scr), siRNA targeting HO-1, HO-2, BACH-1, or HO-1 and BACH1 siRNA using Lipofectamine 
RNAiMax, or treated with Lipofectamine RNAiMAX alone (-). After 3 days, cells were harvested 
for Western blot and supernatants were collected for measurement of extracellular glutamate 
content. (A) Western blot of cell lysates collected on day 3 showing expression of HO-1, HO-2, 
and BACH1 proteins. (B) Supernatant glutamate concentration presented as mean ± SEM in n=3 
technical triplicates.   
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Figure 4.3 Immune activators decrease extracellular glutamate concentrations in human 
primary astrocytes. 
Human primary fetal astrocytes were exposed to TNFα (10ng/mL), LPS (1µg/mL), and IFNγ 
(10ng/mL) alone or in combination and medium and treatments were replaced every 3 days. 
Extracellular glutamate concentration was measured in supernatants collected (A) 24 hours after 
exposure and (B) 15 days after exposure. Data represent mean ± SEM of (n=4 biological 
replicates). Statistical comparisons made by RM ANOVA with post-hoc Holm Sidak test. **P < 
0.01, **P < 0.001 vs. vehicle (gray bar). ##P < 0.01 vs. Untreated (UT).     
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Figure 4.4 Intracellular and extracellular concentrations of glutamate 24 hours post-media 
change are not altered by 3-day pre-treatment with SnMP. 
Rat primary astrocytes were pre-treated with 20µM SnMP (or NaOH vehicle) to inhibit enzymatic 
activity of HO-1 (and HO-2). After 72 hour treatment with SnMP, media and treatment were 
replaced and cells and supernatants were collected immediately (0h) or 24 hours later for HPLC 
analysis of amino acid concentrations. (A) Western blot of rat astrocyte protein lysates prepared 
in parallel. Inhibition of HO enzymatic activity by SnMP is expected to increase expression of HO-
1 protein. (B) Amino acid content in cell lysates (intracellular, blue) and supernatant (extracellular, 
yellow) was measured by HPLC (n=1). 
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Figure 4.5 The Amplex Red Glutamic Acid assay kit is not reliable for measurement of 
glutamate in rat astrocyte supernatants.   
Measurement of glutamate concentration by HPLC and the Amplex Red Glutamic Acid assay kit 
were compared using aliquots of the same rat primary astrocyte supernatants. Supernatants were 
also tested in the Amplex Red Glutamic Acid assay kit after deproteinization in an attempt to 
remove interfering substances present in the culture media.  
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CHAPTER 5: Summary and Conclusions 
The introduction and widespread use of antiretroviral therapy (ART) has significantly improved 
the clinical course of HIV infection, transforming what was once a rapidly lethal disease into a 
manageable chronic condition (2, 159). Despite the many benefits of ART, neurological 
complications of HIV infection persist at significant rates in ART-treated individuals and represent 
a substantial clinical challenge in the management of HIV infection, as underscored by 3-fold 
higher risk of mortality in individuals diagnosed with HIV-associated  neurocognitive disorders 
(HAND) (30). Given that ART remains the only available treatment for HAND, the continued 
prevalence of asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder 
(MND) in ART-treated individuals highlights a critical need for novel therapeutic approaches 
targeting neuropathological processes, including inflammation and oxidative stress, that persist 
within the CNS and periphery of HIV-infected individuals (31, 32, 145, 148). To this end, we 
previously identified a significant reduction in heme oxygenase-1 (HO-1) protein, an inducible 
cytoprotective enzyme, within the dorsolateral prefrontal cortex (DLPFC) of HIV-infected 
individuals that correlated with HAND and markers of CNS immune and macrophage activation. 
Furthermore, our in vitro studies in monocyte-derived macrophages demonstrated that reduced 
HO1 protein expression is a conserved phenotype of HIV infection and is associated with 
neurotoxic levels of extracellular glutamate. These data identify HO-1 protein loss as a host factor 
contributing to HIV-associated excitotoxic injury and furthermore identify HO-1 induction as a 
promising therapeutic approach for neuroprotection in ART-treated HIV-infected individuals.  
 
In the current work, we sought to further define the role of HO-1 in HIV neuropathogenesis by 
determining the mechanism of HO-1 protein reduction in HIV-infected brain and by elucidating 
mechanisms by which HO-1 modulates glutamate handling functions. We have now identified 
enhanced degradation of HO-1 protein in astrocytes as a novel post-transcriptional mechanism 
regulating HO-1 expression that likely contributes to HO-1 protein loss in HIV-infected brain. In 
our examination of the same post-mortem autopsy cohort in which we previously identified 
reduced HO-1 protein in the dorsolateral prefrontal cortex (DLFPC) of HIV-infected individuals, 
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we have now determined that HO-1 RNA is significantly increased and negatively correlated with 
HO-1 protein in HIV-infected individuals. Furthermore, expression of immunoproteasome subunits 
LMP7 and PA28α negatively associated with HO-1 protein in HIV-infected individuals, but 
positively associated with HO-1 RNA in both HIV-infected and non-infected individuals, 
suggesting that post-transcriptional loss of HO-1 protein and induction of immunoproteasome 
subunits may share a common mechanism driven by HIV infection. This post-transcriptional loss 
of HO-1 protein and induction of immunoproteasome subunits was recapitulated by prolonged in 
vitro exposure of human primary fetal astrocytes to IFNγ, an HIV-associated immune activator. 
Additionally, we demonstrated that IFNγ-driven induction of immunoproteasomes is accompanied 
by a progressive loss of constitutive proteasomes over time in human primary fetal astrocytes and 
furthermore determined that IFNγ significantly enhanced the rate of proteasome-dependent HO-1 
degradation. Together, our studies identify a critical role for IFNγ in mediating HIV-associated 
HO-1 protein loss in the brain and provide compelling evidence that IFNγ promotes enhanced 
degradation of HO-1 by immunoproteasome complexes within astrocytes.  
 
IFNγ is chronically elevated during HIV infection, with increased levels of IFNγ and neopterin, an 
indirect measure of IFNγ activity that is primarily produced by macrophages as a by-product of 
GTP metabolism, reported in both serum and cerebrospinal fluid of HIV-infected individuals 
compared to non-infected individuals (CSF) (54, 58, 60, 61, 66, 163, 210). Within the brain 
parenchyma, increased IFNγ has been reported in the temporal lobe, cortex, and cortical white 
matter of HIV-infected individuals as compared to non-infected individuals (62, 66). Although viral 
suppression with ART attenuates CSF levels of neopterin, ART-treated HIV-infected individuals 
still have elevated CSF neopterin compared to non-infected individuals (58, 210). In contrast to 
these studies associating HIV infection with increased IFNγ, a recent study found no significant 
difference in plasma IFNγ levels in HIV-infected and non-infected individuals, but the authors 
speculated that the lack of significance may reflect the wide range of IFNγ measured in non-
infected individuals (211). However this same study identified a biomarker cluster that 
distinguished both viremic and aviremic HIV-infected individuals from non-infected individuals that 
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consisted of 2 IFNγ stimulated gene products (CXCL9, CXCL10), the T cell activation marker sIL-
2R, and monocyte activation marker sCD14, further emphasizing the role of IFNγ in driving 
continued immune activation in HIV-infected individuals regardless of ART status (211). In 
additional work from this same group, IFNγ was significantly increased in the CSF of aviremic 
HIV-infected individuals compared to non-infected individuals and elevated IFNγ was identified as 
one of the top 3 CSF markers distinguishing aviremic HIV-infected individuals from non-infected 
controls (54).  
 
Within the CSF of aviremic HIV-infected individuals, IFNγ has been detected in the range of 
2pg/mL – 10pg/mL, which is well below the concentration of 10ng/mL IFNγ used for in vitro 
experiments in the current body of work (54). However, the degree to which CSF concentrations 
reflect concentrations within brain parenchyma and within local microenvironments is not 
completely understood. IFNγ has a relatively short half-life in vivo following systemic 
administration: serum concentrations are measurable for up to 4 hours after intravenous (IV) 
administration and after intramuscular (IM) administration IFNγ half-life is approximate 4.5 hours 
with peak serum concentrations reached 4-8 hours after administration (212-215). Local IFNγ 
concentrations within specific microenvironments are presumably more important than levels 
within the blood or CSF as IFNγ is produced in a paracrine fashion, secreted locally from 
producing cells and diffusing to neighboring cells within the surrounding microenvironment to 
exert biological effects, the relevance of IFNγ concentrations detected in the blood stream and 
CSF are unclear (216, 217). Detection of IFNγ in the blood stream or CSF likely reflect high 
concentration of IFNγ produced locally that then diffuse across the entire body, resulting in 
significant dilution and metabolism (216, 218). Furthermore, IFNγ binds to extracellular matrix and 
cell surface heparin sulfate proteoglycan which increases local concentrations of this cytokine 
that are not accounted for when measuring IFNγ in the bloodstream and CSF (219-222). IFNγ 
displays a high affinity for binding heparin sulfate molecules, which are distributed ubiquitously in 
vivo, and accumulation of radiolabeled IFNγ in vivo correlates with the known tissue distribution of 
heparin sulfate molecules, suggesting that heparin sulfate molecules regulate local IFNγ 
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concentrations (223-225). In addition to sequestering IFNγ at local sites, heparin sulfate 
molecules also preserve the biological activity of IFNγ by protecting the carboxyl-terminal from 
proteolytic cleavages that decrease the biological activity of IFNγ (223, 226).  
 
Reduced expression of HO-1 protein was associated with induction of immunoproteasome 
subunits in DLPFC of HIV-infected individuals and in human primary astrocytes exposed to IFNγ 
for 15-days, but our in vitro studies suggest that IFNγ-driven HO-1 protein loss is strongly 
associated with loss of constitutive proteasome subunits. Newly synthesized immunoproteasome 
subunits do not replace corresponding constitutive subunits within existing proteasome 
complexes, but rather are preferentially incorporated over constitutive subunits during the 
biogenesis of de novo complexes (114, 127). Given that IFNγ does not alter the total cellular 
proteasome content and induction of immunoproteasome complexes occurs at the expense of 
constitutive proteasome complexes, IFNγ effectively shifts the balance of cellular proteasome 
activity and over time immunoproteasomes become the primary source of cellular proteasome 
activity (127). Our in vitro studies demonstrated that IFNγ-driven HO-1 protein loss required 
prolonged (15-day) exposure to sufficiently high concentrations (>1ng/mL) that were also 
associated with enhanced loss of constitutive proteasome subunits, suggesting that a functional 
shift to immunoproteasome activity is necessary for HO-1 protein reduction in astrocytes. Despite 
significant induction of immunoproteasome subunits, HO-1 protein was not reduced after 
prolonged exposure of astrocytes to TNFα, likely due to the continued presence of constitutive 
proteasome subunits which may prevent enhancement of immunoproteasome activity.  
 
Although loss of constitutive proteasome subunits and concurrent shift to immunoproteasome 
activity appears to be a necessary component of the post-transcriptional mechanism driving HO-1 
protein loss, the extend to which constitutive proteasome subunit expression is decreased in HIV-
infected brain is not clear. Previously, protein expression of the constitutive proteasome subunits 
β1, β2, and β5 was examined in a subset of HIV-infected and non-infected individuals from our 
human post-mortem cohort (n=8 per group) and although no significant differences were 
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identified in DLPFC and white matter, additional analysis of expression within the full cohort 
(n=156) should be undertaken to determine the state of constitutive proteasome subunits in HIV-
infected brain (144). Although our Western blot analyses in vitro demonstrated that prolonged 
exposure to IFNγ produces a significant 10-100 fold induction of LMP2, LMP7, and PA28α 
immunoproteasome subunits and a near complete loss of β1, β2, and β5 constitutive proteasome 
subunits and provides compelling evidence that the balance of cellular proteasome content is 
shifted to immunoproteasome complexes, Native SDS-PAGE techniques should be utilized in 
future experiments to directly determine proteasome complex composition in both in vivo brain 
tissue and in vitro cell culture samples. In this method, intact proteasome complexes are isolated 
by immunoprecipitation, subjected to SDS-PAGE, and expression of specific subunits within 
uncapped 20s complexes, 11s-capped 20s complexes (immunoproteasomes) and 19s-capped 
20s complexes (26s; constitutive proteasomes) can be compared across treatment or disease 
conditions, thus providing a more direct measure of the relative ratio of immunoproteasome and 
constitutive proteasomes in a given condition.  
 
To determine if IFNγ enhances degradation of HO-1 protein, we performed in vitro radiolabeled 
pulse-chase experiments to measure HO-1 protein half-life. In U251 cells, the measured HO-1 
protein half-life of ~14 hours was significantly reduced to ~7.7 hours after 3-day exposure to IFNγ, 
representing a nearly 2 fold increase in the rate of HO-1 protein degradation. Pre-treatment with 
MG-132, an inhibitor of constitutive and immunoproteasome activity, significantly increased the 
amount of radiolabeled HO-1 protein remaining at each time point and thus the degradation of 
HO-1 protein was mediated, at least in part, by proteasomal activity. Although we can not rule out 
a contribution of constitutive proteasome activity to HO-1 degradation in IFNγ exposed cells, the 
effects of MG-132 in IFNγ exposed cells likely reflect inhibition of immunoproteasome activity as 
these cells had robust induction of immunoproteasome subunits (7-fold increase in LMP7; 50-fold 
increase in LMP2) and significant loss of constitutive subunits (35% decrease in β5; 50% 
decrease in β1). Although IFNγ decreased constitutive proteasome subunit expression (and 
presumably decreased activity of constitutive proteasomes), MG-132 restored HO-1 to 
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comparable levels in both vehicle and IFNγ conditions, thus the efficacy of MG-132 in IFNγ 
exposed cells is not likely mediated solely by inhibition of constitutive proteasome activity and is 
at least partially attributable to inhibition of immunoproteasome activity. Additional experiments 
using immunoproteasome specific inhibitors such as ONX-0914 should be performed to 
determine the relative contribution of immunoproteasome and constitutive proteasome activity to 
IFNγ-driven HO-1 degradation.  
 
The specific mechanisms by which immunoproteasome induction increases degradation of HO-1 
protein is not yet clear, but may reflect differences in the enzymatic activity and substrate 
preferences of immunoproteasome complexes. Although constitutive and immunoproteasome 
complexes generate qualitatively similar pools of antigenic peptides, constitutive and 
immunoproteasome catalytic subunits exhibit subtle differences in cleavage site usage and 
cleavage velocities which leads to quantitative differences in the pool of antigenic peptides 
produced by proteasome complex subtypes (109, 119-123). Immunoproteasome complexes have 
enhanced preference for cleavage after C-terminal hydrophobic and basic residues, resulting in 
increased production of these peptide fragments, which represent the preferred C-terminus of 
MHC class I epitopes, as compared to constitutive proteasome complexes (109, 114, 119). The 
human HO-1 protein may be a preferred substrate of the immunoproteasome catalytic subunits 
due the high degree of hydrophobicity (Fig 5.1A) and presence of basic amino acid residues (Fig 
5.1B) within the C-terminal region, leading to an increased rate of degradation by 
immunoproteasome complexes. The 11s immunoproteasome regulatory complex, consisting of 
PA28α and PA28β subunits, may enhance degradation of HO-1 protein as binding of this 
complex to the 20s catalytic complex induces conformational changes within the catalytic 
subunits that alters the accessibility of active site pockets and their binding affinity for substrate 
protein sequences (227). Given that both IFNγ and HIV infection induce oxidative stress and are 
associated with protein oxidation, HO-1 may itself be a target of protein oxidation and this 
modification could further enhance the degradation of HO1 by immunoproteasome complexes, 
which are thought to be more efficient at degrading oxidant damaged proteins than constitutive 
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proteasome complexes (116, 228). Alternatively, IFNγ may alter upstream processes of the 
ubiquitin proteasome system (UPS) to enhance the availability of HO-1 protein at 
immunoproteasome complexes. Intramembrane cleavage of HO-1 by signal peptide peptidase 
(SPP) and ubiquitination by the E3 ubiquitin ligase TRC8 are critical for removal of this tail-
anchored protein from the ER and subsequent proteasomal-dependent degradation, and IFNγ 
may potentially enhance one or both of these processes leading to increased HO-1 availability at 
proteasome complexes (100, 154, 229, 230).  
 
 
Figure 5.1 Hydrophobic and basic amino acid residues in full length human HO-1 protein.  
Amino acid properties of the full length human HO-1 protein (288 amino acids) were determined 
using EMBOSS Pepinfo software (231). (A) Hydrophobicity plot generated using Kyte & Doolittle 
hydropathy parameters. Value of 0 represents average hydrophobicity (red line), positive values 
represent hydrophobic regions, negative values represent hydrophilic regions. (B) Histogram 
depicting the presence of basic amino acids (Lysine, Arginine, Histidine) at each amino acid 
residue.  
 
The post-transcriptional loss of HO-1 protein observed after prolonged exposure of human 
primary astrocytes to IFNγ was not recapitulated in rat primary astrocytes exposed for 15-days to 
the same concentration of IFNγ, suggesting that mechanisms regulating HO-1 expression and/or 
98  
IFNγ signaling may be divergent between rat and human species. In addition to regulation by 
numerous transcription factors and signaling pathways, HO-1 gene expression in humans is also 
modulated by alternative splicing, single nucleotide polymorphisms (SNPs), and a (GT)n 
microsatellite repeat within the promoter region providing numerous potential points of divergence 
between human and rat species (150, 232, 233). In rats, HO-1 is considered a bona fide heat 
shock protein and is transcriptionally regulated by members of the heat-shock factor (HSF) family 
through binding to heat shock element (HSE) consensus regions within the promoter region, but 
in humans and mice the HSE loci are mutated and functionally inactive, thus human and mouse 
HO-1 is not regulated by HSF is not considered a heat shock protein (150). Given that our data 
demonstrated significant reduction in HO-1 protein in both human and rat astrocytes after 
prolonged exposure to LPS + IFNγ, regulation of HO-1 expression by immune activators appears 
to be at least partially conserved across species. The general regulation and function of 
immunoproteasomes is similar in humans and rats, but a detailed understanding of 
immunoproteasome regulation and function in rat astrocytes is lacking. Thus, future experiments 
should determine the effects of various HIV-relevant immune activators on expression of 
constitutive and immunoproteasome subunits in rat astrocytes and examine potential 
relationships between immune activation, proteasome complexes, and HO-1 expression.  
 
We previously demonstrated that HIV-infection of monocyte-derived macrophages (HIV-MDM) 
significantly reduces HO-1 protein and is associated with supernatant neurotoxicity and enhanced 
extracellular levels of glutamate (170). In HIV-MDM, selective knockdown of HO-1 expression 
and inhibition of heme oxygenase (HO-1 and HO-2) enzymatic activity enhanced neurotoxicity 
and extracellular glutamate while pharmacological and genetic induction of HO-1 expression in 
HIV-MDM attenuated neurotoxocity and extracellular glutamate, suggesting a functional role for 
HO-1 in modulating glutamate handling in HIV-MDM and perhaps other cell types (170). In the 
current work, modulation of HO-1 in astrocytes by pharmacological inhibition of HO enzymatic 
inhibition, siRNA mediated knockdown, and siRNA mediated induction did not alter glutamate 
uptake, extracellular glutamate levels, or flux of glutamate (and other amino acids) to intracellular 
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and extracellular compartments. Similarly, in healthy, non-infected monocyte-derived 
macrophages modulation of HO-1 by siRNA mediated knockdown did not alter extracellular 
glutamate levels (unpublished data) suggesting that HO-1 may regulate glutamate handling only 
under certain conditions associated with cell stress or injury. Given that HO-1 expression is 
induced in response to numerous cellular insults, HO-1 expression is not likely to be important for 
regulation of cellular functions under homeostatic conditions. We speculate that during conditions 
of cellular injury or stress that induce HO-1, cellular functions such as glutamate handling may be 
modulated by HO-1 and furthermore, if HO-1 induction is prevented, such as in HIV-MDM, the 
lack of HO-1 expression could potentially dysregulate glutamate handling and other cellular 
functions. Although the mechanism by which induction of HO-1 modulates glutamate is currently 
unclear, products of the enzymatic activity of HO-1 may potentially regulate glutamate handling 
functions. Under conditions of peroxynitrate-induced nitrosative stress, carbon monoxide (CO) 
produced as by HO-1 catalyzed degradation of heme increased expression of the catalytic 
subunit of glutamate-cysteine ligase (GCLC) (234). GCLC is the rate limiting enzyme in the 
synthesis of glutathione from glutamate and enhanced activity of GCLC would increase the 
metabolism of glutamate through the glutathione pathway, suggesting a potential mechanism by 
which induction of HO-1 would have beneficial effects for glutamate handling. Although our 
preliminary analyses of glutamate handling in astrocytes was not able to identify a function role 
for HO-1, this work provides an important framework for future experiments as it has established 
the technical feasibility of additional approaches for examining glutamate handling and for 
modulating HO-1 expression in primary human astrocytes.  
 
These data identify enhanced degradation of HO-1 protein by immunoproteasome complexes in 
astrocytes as a plausible mechanism by which HIV infection reduces HO-1 protein in the brain 
and furthermore establish a critical role for IFNγ in driving HIV neuropathogenesis. IFNγ is a 
critical component of the host immune response to viral infection and intracellular pathogens, 
regulating immune activation and responses across a broad repertoire of cell types. In the current 
work we have demonstrated that IFNγ induces expression of HO-1 RNA, likely as a 
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cytoprotective response. Corresponding induction of HO-1 protein would enhance enzymatic 
degradation of free heme, which is present intracellularly to support the normal physiological roles 
of heme (erythroid gene translation, regulation of miRNA processing, circadian rhythms, and ion 
channel function) and degradation of intracellular hemoproteins (cytochromes, oxidases, 
peroxidases, catalyases, and synthases) contributes to this pool of free heme that is maintained 
despite the constitutive expression of HO-2. This implies that within the cell, free heme is 
available as a substrate for HO-1 enzymatic activity and induction of HO-1 may exert 
cytoprotective effects through increased generation of the anti-inflammatory and antioxidant 
products carbon monoxide (CO), biliverdin, and bilirubin. In addition to induction of HO-1 RNA, 
our data demonstrate that IFNγ also progressively induces expression of immunoproteasome 
complexes at the expense of constitutive proteasome complexes. Immunoproteasome induction 
has several beneficial effects including generation of antigenic peptides for MHC class I molecule 
presentation and enhanced degradation of oxidatively-damaged proteins. In the current work, we 
demonstrated that immunoproteasomes degrade HO-1 protein more rapidly than constitutive 
proteasomes and this may be an attempt to attenuate the continued induction of HO-1 driven by 
IFNγ. Although the cytoprotective properties of HO-1 are well documented across a broad 
spectrum cell types and diseases, prolonged induction of HO-1 has been suggested to be 
detrimental to cell health and survival, particularly within the CNS, and immunoproteasome-
mediated degradation of HO-1 could serve to restore expression of HO-1 to homeostatic levels 
(103). Induction of immunoproteasomes is intended to be a transient response that can be rapidly 
turned off once immunoproteasome activity is no longer needed, thus the enhanced degradation 
of HO-1 by immunoproteasomes would also be a transient response. In the absence of IFNγ, 
immunoproteasome complexes are quickly lost and replaced by constitutive proteasome 
complexes, likely reflecting the intrinsically short half-life of immunoproteasome complexes 
(~27h) as compared to constitutive proteasomes (~133h) (131). However during prolonged 
exposure to IFNγ, as in chronic HIV infection, immunoproteasome subunits are continually 
induced and immunoproteasome complexes persist over time. This persistent expression of 
immunoproteasome complexes dramatically shifts the balance between constitutive proteasome 
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and immunoproteasome activity that may have unintended pathological consequences such as 
significant loss of HO-1 protein.  
 
This body of work suggests casual links between CNS immune activation, immunoproteasome 
induction, and enhanced HO-1 degradation that could contribute to neuropathogenesis not only in 
HAND but also other neurodegenerative disorders associated with increased IFNγ, chronic 
immune activation, and oxidative stress. Induction of immunoproteasome subunits has been 
reported in several neurodegenerative disorders including Alzheimer’s disease, multiple sclerosis, 
and epilepsy, and it has been suggested that selective inhibition of immunoproteasome activity 
may be of benefit in these and other systemic inflammatory diseases (141, 235-238). Targeted In 
vivo inhibition of immunoproteasome activity with the LMP7-selective inhibitor ONX-0914 
(previously PR-957; selectively) attenuated disease progression in mouse models of rheumatoid 
arthritis, dextran sodium sulfate-induced colitis, and experimental autoimmune encephalomyelitis 
(EAE) and in these models ONX-0914 reduced infiltration of immune cells, attenuated cytokine 
production, and decreased Th1 and Th17 differentiation of CD4+ T cells (239-241). Although 
inhibition of LMP7 activity attenuates immune activation in vivo and could potentially restore HO-1 
protein expression in HIV-infected individuals, the clinical relevance of such a therapeutic 
approach is limited given the many functions of immunoproteasome complexes. In the case of 
HIV infection, although immunoproteasomes are likely driving the loss of HO-1 protein in the 
brain, activity of these complexes is also likely to have beneficial effects important for cell health 
and survival in the face of continued viral replication, immune activation, and oxidative stress. 
Inhibition of immunoproteasome activity or loss of immunoproteasome subunit expression is 
associated with decreased MHC Class I molecule antigen presentation, reduced CD8+ T cell 
levels and responses, impaired degradation of oxidized proteins, and dysregulation of intracellular 
signaling pathways (118). Given the numerous functions and critical roles of 
immunoproteasomes, the negative consequences of inhibiting immunoproteasome activity likely 
outweigh the proposed benefit of restoring HO-1 protein expression in HIV-infected individuals.  
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We have previously proposed induction of HO-1 as a promising adjunctive therapeutic strategy 
for neuroprotection in ART-treated, HIV-infected individuals and we previously identified dimethyl 
fumarate (DMF) as an especially relevant HO-1 inducer. DMF and its primary metabolite 
monomethyl fumarate (MMF) are potent inducers of HO-1 expression and also exert numerous 
anti-inflammatory effects that would likely provide additional therapeutic benefit in HIV-infected 
individuals. Importantly, DMF has been demonstrated to be safe and well tolerated and in 2013 a 
CNS-penetrant oral formulation of DMF, TecfideraTM, was approved by the FDA for the treatment 
of multiple sclerosis, a CNS disease characterized by recurrent neuroinflammation and oxidative 
stress. DMF and MMF induce the Nrf2-dependent antioxidant response pathway which leads to 
transcriptional upregulation of HO-1 expression. We have previously demonstrated in vitro that 
therapeutically relevant concentrations of DMF increases HO-1 protein expression and reduces 
neurotoxic levels of glutamate in HIV-infected monocyte-derived macrophages. It is unclear if 
DMF will similarly restore HO-1 protein levels in astrocytes exposed to IFNγ, as transcriptional 
induction of HO-1 may not be sufficient to overcome the enhanced rate of HO-1 protein 
degradation in IFNγ exposed astrocytes. However DMF and MMF decrease IFNγ production in 
multiple cell types including T-lymphocytes, dendritic cells, and monocyte/macrophages, 
suggesting that within the CNS of HIV-infected individuals, DMF may attenuate the production of 
IFNγ and lead to reduced expression of immunoproteasomes in astrocytes (169). We speculate 
that the dual effects of HO-1 gene induction and immunoproteasome suppression mediated by 
DMF would restore brain HO-1 protein expression in HIV-infected individuals. Additional 
neuroprotective benefits of DMF in HIV-infected individuals include reduced infiltration of 
lymphocytes and monocytes into the brain, inhibition of pro-inflammatory signaling, and inhibition 
of NF-κB signaling. Potent inhibition of HIV replication by DMF/MMF pretreatment in monocyte-
derived macrophages has been demonstrated in vitro, suggesting that initiation of DMF treatment 
in HIV-infected individuals may prevent establishment of new infections in cells and may thus 
contain the size of the CNS viral reservoir over time (105). The continued prevalence of HIV-
associated neurocognitive disorders (HAND) in the post-ART era highlights an urgent need for 
additional pre-clinical and translational studies assessing the efficacy and safety of DMF and 
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other HO-1 inducing compounds that will provide a neuroprotective benefit in HIV-infected 
individuals  
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